The International Liver Congress 2019


10-14 April 2019 Vienna
N. Poster
Poster title
Applicant name
  THU-001 Identifying intrahepatic lymphocyte permutations in active untreated, resistant and treated autoimmune hepatitis Gautham Appanna Received Received
  LBP-001 In NAFLD, alcohol drinking habits and genetics predict progression to advanced liver disease: follow-up of population surveys Fredrik berg Received Received
  SAT-001 Validity of urinary bio markers and cardiac echo in diagnosis of acute kidney injury in patients with liver cirrhosis Amany Abbasy Received Received
  FRI-001 The PBC-10: A validated short clinic symptom screening tool for primary biliary cholangitis Laith Alrubaiy Received Received
  THU-002 Macrophage activation marker neopterin predicts liver transplantation-free survival in primary sclerosing cholangitis Johannes R Hov Received Received
  SAT-002 Lusutrombopag is a safe treatment option for thrombocytopenia in patients with chronic liver disease undergoing an invasive procedure: Pooled safety analysis from 3 studies Nezam Afdhal Received Received
  FRI-002 Sustained remission after treatment withdrawal in autoimmune hepatitis : A multicenter retrospective study Gérard THIEFIN Received Received
  LBP-002 Association between HBsAg loss and long-term clinical outcome in chronic hepatitis B: a systematic review and meta-analysis analysis Ryan Anderson Received Received
  THU-003 European multicenter validation of autoantibodies against huntingtin-interacting protein 1-related protein for the diagnosis of autoimmune hepatitis in adults Bastian Engel Received Received
  LBP-003 LPCN 1144, an Androgen Receptor Agonist Targeted for NASH, Reduces Liver Fat and Key Serum Biomarkers Kilyoung Kim Received Received
  SAT-003 Real-world data demonstrate safety and effectiveness of lusutrombopag in chronic liver disease patients with thrombocytopenia undergoing planned invasive procedures: Interim analysis Nezam Afdhal Received Received
  FRI-003 Early response to corticosteroid treatment supports differentiation of drug-induced liver injury and autoimmune hepatitis Andreas Benesic Received Received
  FRI-004 Cirrhosis status at diagnosis, non-Caucasian descent, treatment response and age determine long term survival in autoimmune hepatitis Maaike Biewenga Received Received
  LBP-004 Investigation of synbiotic treatment in non alcoholic fatty liver disease (NAFLD): Results of the INSYTE study Chris Byrne Received Received
  SAT-004 Bacterial translocation in patients with liver cirrhosis and variceal bleeding Christos Triantos Received Received
  THU-004 Lactobacillus rhamnosus GG prevents liver fibrosis through intestinal FXR/FGF15-mediated inhibition of bile acid synthesis and the increase of bile acid excretion in mice Wenke Feng Received Received
  THU-005 Activation regulators of peripheral blood and intrahepatic T effector cells in autoimmune hepatitis Pamela Filpe Received Received
  LBP-005 classification and mutation prediction based on liver cancer hisopathological images using deep learning Mingyu Chen Received Received
  FRI-005 Characteristics and outcome of autoimmune hepatitis-primary biliary cholangitis and autoimmune hepatitis-primary sclerosing cholangitis overlap patients compared to autoimmune hepatitis patients Maaike Biewenga Received Received
  SAT-005 Prognostic factors associated with mortality of acute variceal hemorrhage in cirrhotic patients : Multi-center results Kuntapon Akkarachinores Received Received
  LBP-006 High Seroprotection Rates Achieved with Two Doses of Sci-B-Vac, a Third Generation Hepatitis B containing PreS1, PreS2 and S Antigens. Francisco Diaz-Mitoma Received Received
  SAT-006 Efficacy of oral thrombopoietin receptor agonist lusutrombopag in chronic liver disease by underlying disease aetiology Naim Alkhouri Received Received
  THU-006 Aberrant DNA methylation in bile accurately detects cholangiocarcinoma in patients with primary sclerosing cholangitis Trine Folseraas Received Received
  FRI-006 Soluble CD163 and mannose receptor as markers of liver disease severity and long term prognosis in patients with primary biliary cholangitis Lars Bossen Received Received
  FRI-007 Serum markers of macrophage activation CD163 and Mannose receptor predict transplant-free survival in primary sclerosing cholangitis Lars Bossen Received Received
  LBP-007 Association of pharmacogenomics and pharmacokinetics with antiviral activity of Pradefovir for treatment of chronic hepatitis B infection. Qingmei Li Received Received
  SAT-007 Survival and risk factors of mortality after emergency transjugular intrahepatic portosystemic shunt for uncontrolled acute variceal bleeding caused by cirrhosis-related portal hypertension Manon Allaire Received Received
  FRI-008 Incidence, prevalence and mortality of primary sclerosing cholangitis in Italy: A population-based study Marco Carbone Received Received
  LBP-008 The Worlds Largest Hepatitis C Screening Program in Egypt Magdi El-Serafy Received Received
  SAT-008 Quality of medical care measurement in hepatic cirrhosis outpatients: Is there room for improvement? Alberto Amador Received Received
  SAT-009 Pharmacokinetics of ertapenem in plasma and ascitic fluid in cirrhotic patients with spontaneous bacterial peritonitis Alberto Amador Received Received
  FRI-009 Bezafibrate add-on therapy in high-risk primary biliary cholangitis is associated with prolonged predicted survival even in patients with incomplete biochemical improvements Christophe Corpechot Received Received
  LBP-009 Liver humanization of Fah -/- /Rag2 -/- /Il2rg -/- NOD mice with human hepatocytes homozygous for M148I PNPLA3 allows the assessment of specific genotype contribution to NASH development in vivo. Lander Foquet Received Received
  THU-009 High throughput RNA sequencing unravels pathways associated with cognitive deficit in primary billiary cholangitis Lucy Gee Received Received
  FRI-010 Bezafibrate add-on therapy in high-risk primary biliary cholangitis is associated with an improvement of fibrometer and fibrometer-VCTE, two high-accuracy non-invasive fibrosis tests extensively validated in frequent chronic liver diseases Christophe Corpechot Received Received
  THU-010 Shedding light on the X chromosome contribution to the genetic architecture of primary biliary cholangitis Alessio Gerussi Received Received
  LBP-010 A structurally engineered fatty acid, icosabutate, rapidly normalises elevated plasma ALT and gamma-glutamyl transferase (GGT) concentrations in a study population at high risk of NAFLD/NASH David Fraser Received Received
  SAT-010 Predictors of mortality in Child B cirrhotic patients with acute variceal bleeding Alberto Amador Received Received
  LBP-011 Is it possible to successfully link migrants from low-income countries to HBV, HCV, and HIV services upon arrival in the European Union? Jeffrey V Lazarus Received Received
  FRI-011 Ductular reaction, intermediate hepatocites and fibrosis extension correlate with prediction of treatment failure to ursodeoxycholic acid in primary biliary cholangitis Laura Cristoferi Received Received
  THU-011 Cholecystectomy causes worsening of primary sclerosing cholangitis features in Abcb4 knockout mice Ester Gonzalez-Sanchez Received Received
  SAT-011 Cirrhotic patients:Is there any role to malnutrition in predicting mortality? Cátia Arieira Received Received
  FRI-012 Analysis of clinical and histological factors to differentiate autoimmune hepatitis of drug induced liver injury Lidia Cuevas del Campo Received Received
  LBP-012 Phase 1a Study of the Safety, Tolerability and Pharmacokinetics of ABI-H2158, a Novel Second-Generation HBV Core Inhibitor, in Healthy Volunteers Edward Gane Received Received
  THU-012 Prevalence of autoimmune liver disease related autoantibodies in various non autoimmune liver diseases Rakesh Kumar Jagdish Received Received
  SAT-012 Alterations in skin microbiota, serum bile acids and autotaxin modulate itching intensity in patients with cirrhosis JASMOHAN BAJAJ Received Received
  SAT-013 Potentially Preventable readmissions and complications in hospitalized patients with hepatic encephalopathy in a large multi-center cohort JASMOHAN BAJAJ Received Received
  THU-013 Investigating the potential immunomodulatory role of mesenchymal stromal cells in primary sclerosing cholangitis Ashnila Janmohamed Received Received
  LBP-013 Effect of treatment of hepatitis B patients with tenofovir disoproxil or entecavir on risk of hepatocellular cancer death in a U.S. Cohort Lora Rupp Received Received
  FRI-013 A combined blood and MR imaging risk score for monitoring liver inflammation in paediatric AIH Andrea Dennis Received Received
  LBP-014 Magnetic Resonance Biomarkers for Early Phase Steatohepatitis Clinical Trials: Short Term Evaluation in Adolescents, Transitoriness or Stability in Steatosis (STEATOSIS) Nidhi Goyal Received Received
  SAT-014 Efficacy of rifaximin soluble solid dispersion in patients with early decompensated cirrhosis and a Conn score of 0: A post hoc analysis of a randomized, double-blind, placebo-controlled trial Jasmohan Bajaj Received Received
  FRI-014 Diagnostic criteria for autoimmune hepatitis: what is a normal IgG? Jessica Dyson Received Received
  THU-014 Primary sclerosing cholangitis-associated biliary neoplasia demonstrates a high inter- and intratumour heterogeneity Eline Kamp Received Received
  THU-015 Mutational signatures during the neoplastic cascade towards cholangiocarcinoma in primary sclerosing cholangitis Eline Kamp Received Received
  FRI-015 Environmental triggering in primary biliary cholangitis: Disease risk relates to coal mining activity Jessica Dyson Received Received
  LBP-015 Urinary Liver Fatty-Acid-Binding Protein (uL-FABP) improves accuracy of MELD score to predict short-term mortality in patients with decompensated cirrhosis Adria Juanola Received Received
  SAT-015 Sarcopenia is associated with a worst prognosis in cirrhotic patients in the context of liver transplantation Chantal Bemeur Received Received
  LBP-016 Phase II trial to evaluate immunogenicity and safety of a new adjuvanted HBAI20 Hepatitis B vaccine in non-responders: BE RESPONDER. zgr Koc Received Received
  SAT-016 Impact of sarcopenia in patients undergoing transjugular intrahepatic portosystemic shunt insertion for refractory ascites Amine Benmassaoud Received Received
  THU-016 Loss of signaling through the G-protein coupled bile acid receptor Tgr5 confers protection from fibrosis in the progressive cholangiopathy of Mdr2-/- mice Nelson Matuschek Received Received
  SAT-017 Anticoagulant effect of edoxaban in patients with cirrhosis: The POET study Sarah Bos Received Received
  FRI-017 High prevalence of possible PSC recurrence post transplant evaluated by protocol biopsies Lise Katrine Engester Received Received
  LBP-017 Robust Mucosal-associated invariant T (MAIT) cell activation in response to interactions with primary human liver cell subsets Martin Lett Received Received
  SAT-018 Relation of CT determined sarcopenia and anthropometry to serum C-reactive protein levels in patients with chronic liver disease Sarah Brown Received Received
  LBP-018 Effect of Obeticholic Acid on Liver Function in Patients with Fibrosis due to NASH Kjersti Swearingen Received Received
  THU-018 c-Jun N-terminal kinases act synergistically in hepatocytes to protect mice from cholestatic liver injury Mohamed Ramadan Mohamed Received Received
  FRI-019 Readmission in hospitalized patients with autoimmune hepatitis in nationwide inpatient setting Xiaowen Fan Received Received
  THU-019 Impact of metabolic stress on the pathogenesis of autoimmune liver disease in subjects bearing missense variant of negative immune regulator Lnk/Sh2b3 Taizo Mori Received Received
  LBP-019 NGM282 Promotes HDL Biogenesis and Transhepatic Cholesterol Efflux to Prevent Atherosclerosis in Mice Lei Ling Received Received
  SAT-019 Minimal hepatic encephalopathy: Which test should we use in clinical practice? Benjamin Buchard Received Received
  THU-020 Postprandial changes in the hepatic bile acid transport in healthy human subjects measured by 11C-CSar PET/CT Nikolaj Worm rntoft Received Received
  SAT-020 Transjugular intrahepatic portosystemic shunt implantation improves renal function in patients with ascites Theresa Bucsics Received Received
  FRI-020 Identification of risk factors for histological progression with sequential liver biopsies in primary cholangitis patients Yukihisa Fujinaga Received Received
  LBP-021 Effect of NGM282, an FGF19 Analogue, on Pruritus in Patients with Primary Sclerosing Cholangitis: Analysis of a Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Marlyn J. Mayo Received Received
  SAT-021 How to use platelets and liver stiffness to rule out esophageal varices needing treatment? Paul Cales Received Received
  FRI-022 Characteristics of autoimmune hepatitis with acute presentation Ana Gómez Received Received
  SAT-022 Transjugular intrahepatic portosystemic shunts is still an effective treatment for refractory variceal haemorrhage in patients with high MELD/ Child Pugh scores Rigers Cama Received Received
  LBP-022 Outcome of 119 cirrhotic patients with splanchnic thrombosis: a single center real-life experience Giorgia Micucci Received Received
  THU-022 CM-101- a Novel anti CCL24 monoclonal antibody reduces cholangiocytes proliferation in experimental cholestasis models Neta Barashi Received Received
  FRI-023 Inadequate response to UDCA among PBC patients under routine care in the US: Rising serum bilirubin even in the normal range is a risk factor and subsequent clinical follow-up differs based on treatment response Lora Rupp Received Received
  SAT-023 The lack of benefit of prophylactic transfusions of patients with cirrhosis and esophageal varices undergoing endoscopic variceal ligation Andres Cardenas Received Received
  LBP-024 Safety, tolerability and efficacy of volixibat, an apical sodium-dependent bile acid transporter inhibitor, in adults with non-alcoholic steatohepatitis: 24-week interim analysis results from a phase 2 study Danielle Emery Received Received
  FRI-024 Incidence and prevalence of autoimmune hepatitis in England 1997-2015. A population-based cohort study Lisbet Grnbk Received Received
  SAT-024 Effect of acute kidney injury on long-term outcomes of spontaneous bacterial peritonitis in cirrhotics using ICA-AKI criteria Ju-Yeon Cho Received Received
  FRI-025 Long-term outcome in autoimmune hepatitis: The second twenty years Laura Harrison Received Received
  THU-025 Pathway-analysis using datasets of GWAS and microarray identified IFNG as the most significant upstream-regulator in primary biliary cholangitis Kazuko Ueno Ueno Received Received
  LBP-025 a phase 1 clinical trial of therapeutic vaccine t101 in chronic hepatitis b(chb) patients: a randomized, double-blind, placebo-controlled, single and multiple injections, dose escalation study Xiaomin WANG Received Received
  SAT-026 Mid-arm circumference and triceps skinfold thickness independently predicts mortality in hospitalized patients with decompensated cirrhosis Camila Saueressig Received Received
  FRI-026 Long-term assessment of the effects of obeticholic acid in patients with primary biliary cholangitis on immune and inflammatory markers Emily Plummer Received Received
  THU-026 Natural killer T cells promote cholestatic liver disease in bile duct ligated mice Laura Valestrand Received Received
  LBP-026 Magnetically controlled capsule endoscopy as a noninvasive tool for risk stratification of gastroesophageal varices in compensated cirrhosis (CHESS1801): A prospective multicenter study Xiaolong Qi Received Received
  THU-027 The human apical sodium dependent bile salt transporter (ASBT) activates a bile salt-induced defense in human cholangiocytes Jorrit van Niekerk Received Received
  FRI-027 Serum bile acids significantly associate with the fibrogenesis biomarker Pro-C3: analysis of a randomized, placebo-controlled trial of NGM282 in patients with primary sclerosing cholangitis Gideon Hirschfield Received Received
  SAT-027 Effects of propranolol on liver- and spleen-stiffness measured by MR-Elastography in patients with cirrhosis Karen Vagner Danielsen Received Received
  LBP-027 Preliminary analysis of SuperDOT-C: A cluster randomised controlled trial of pharmacy-led versus conventional treatment for HCV positive patients receiving daily opioid substitution therapy - The Tayside sites Andrew Radley Received Received
  SAT-028 Diabetes is associated with TIPS failure in cirrhotic patients with refractory ascites Stella De Nicola Received Received
  THU-028 Gut derived bacteria, presented by liver dendritic cells can activate liver MAIT cells in primary sclerosing cholangitis Suz Warner Received Received
  LBP-029 BIO89-100, a novel PEG-FGF21 analogue, is efficacious following weekly and every 2-week subcutaneous dosing in spontaneous diabetic cynomolgus monkeys Moti Rosenstock Received Received
  THU-029 Interleukin 23 produced by hepatic monocyte-derived macrophages is essential for the development of primary biliary cholangitis Ehud Zigmond Received Received
  FRI-029 Non-alcoholic fatty liver disease and steatohepatitis in autoimmune hepatitis: important player or innocent bystander? Zachou Kalliopi Received Received
  SAT-029 Prediction of hepatic hydrothorax in cirrhosis patients with ascites Thomas Deleuran Received Received
  FRI-030 Treatment choice and long-term prognosis for elderly PBC Hiroteru Kamimura Received Received
  LBP-030 Changes in Serum Bile Acids Correlate with 7alpha-Hydroxy-4-Cholesten-One and Fibrogenesis Biomarker Pro-C3 with NGM282 Therapy in Patients with Nonalcoholic Steatohepatitis Arun Sanyal Received Received
  SAT-030 Annual contrast-enhanced MRI is highly effective in the surveillance of hepatocellular carcinoma in cirrhotic patients Coskun Ozer Demirtas Received Received
  SAT-031 Bleeding risk-scores for prediction of acute variceal bleeding outcome marwa Elfayoumy Received Received
  THU-031 Hemorrhagic and thrombotic complications in critically patients with cirrhosis William Bernal Received Received
  LBP-031 AXA1665, a novel composition of amino acids restores the dysregulated amino acid profile, lowers ammonia, and improves body composition and function in Child-Pugh class A and B subjects Manu Chakravarthy Received Received
  FRI-031 Association between serum immunoglobulin G levels and intrahepatic plasmacytic gene signature in human autoimmune hepatitis Atsumasa Komori Received Received
  THU-032 Peritoneal CD206 links macrophage heterogeneity in decompensated cirrhosis with outcome of spontaneous bacterial peritonitis Tony Bruns Received Received
  SAT-032 Spleen to liver stiffness ratio significantly differs between ALD and HCV and predicts disease specific complications Omar Elshaarawy Received Received
  FRI-032 Liver transplantation ameliorates chronic fatigue and improves quality of life in patients with primary sclerosing cholangitis Marcin Krawczyk Received Received
  LBP-032 The Natural History of Ferroportin Disease First Results of the International, Multicenter EASL non-HFE Registry Benedikt Schaefer Received Received
  THU-033 Impact of early Hemodynamic correction of AKI in acute on chronic liver failure patients with large ascites Shreya Butala Received Received
  SAT-033 Body fat composition determines outcomes before and after liver transplantation in cirrhosis Cornelius Engelmann Received Received
  LBP-033 Gelesis superabsorbent hydrogel prevents hepatic steatosis in a high fat diet-induced NAFLD pre-clinical model Lauren Rautiola Received Received
  FRI-033 Long-term obeticholic acid treatment is associated with improvements in collagen morphometry in patients with primary biliary cholangitis Emily Plummer Received Received
  LBP-034 Effect of Resistance Associated Substitutions on Retreatment of HCV infected patients with prior failure to Direct Acting Antiviral Therapy David Smith Received Received
  FRI-034 Clinical phenotype of significantly elevated serum IgG4: Single center experience Hadi Kuriry Received Received
  THU-034 Serum metabolite profiling predicts survival in patients with hepatitis B virus related acute-on-chronic liver failure Ermei Chen Received Received
  SAT-034 The psychomotor vigilance task: Role in the diagnosis of hepatic encephalopathy and relationship with driving ability Chiara Formentin Received Received
  FRI-035 Clinical outcomes associated with additional fibrate treatment in UDCA-refractory PBC patients: A multicenter study Cheol-Hyung Lee Received Received
  LBP-035 Kupffer cell development: A link between Notch signaling and LXRa Wouter TJonck Received Received
  SAT-035 The negative impact of skeletal muscle volume loss during transarterial chemoembolization for hepatocellular carcinoma Masashi Fujita Received Received
  THU-035 A shorter period of a subsequent episode of acute decompensation of cirrhosis predicts worse outcome: A single center experience Po-Sung Chu Received Received
  SAT-036 Prognostic implications of encephalopathy to adequately define differentiated stages of decompensated cirrhosis Marta García Guix Received Received
  THU-036 First description of the immune checkpoint receptor landscape in decompensated cirrhosis and ACLF Douglas Corrigall Received Received
  LBP-036 Inhibition of glutamine synthetase in monocytes from patients with Acute-on-Chronic Liver Failure resuscitates their antibacterial and inflammatory capacity Schallk Van der Merwe Received Received
  FRI-037 Change in lipids: Characteristics and response to obeticholic acid in TARGET-PBC, a diverse, large United States real-world cohort Stephanie Watkins Received Received
  THU-037 Soluble MAdCAM-1 as a novel marker of hepatic endothelial dysfunction in acutely decompensated cirrhosis Jonathon Graham Received Received
  SAT-037 Applying the new nutritional screening and assessment algorithm to estimate malnutrition prevalence in Greek cirrhotic patients as suggested by the 2018 EASL nutritional guidelines for chronic liver disease Maria Vasiliki Papageorgiou Received Received
  LBP-038 Increasing Number of Metabolic Co-Morbidities are Associated with Higher Risk of Advanced Fibrosis in Patients with Nonalcoholic Steatohepatitis Robert Wong Received Received
  FRI-038 Good performance of the biochemical response criteria after three months of ursodeoxycholic acid treatment in patients with primary biliary cholangitis Laura Patricia Llovet Received Received
  SAT-038 Lusutrombopag for treatment of thrombocytopenia in patients with chronic liver disease who are undergoing planned invasive procedures: pooled safety analysis of bleeding-related adverse events Edoardo Giovanni Giannini Received Received
  THU-038 Fungal pneumonia in critically ill cirrhotics: Spectrum and outcomes Pratibha Ramchandra Kale Received Received
  THU-039 LPS-induced upregulation of RANTES in a new mouse model of bacterial infection related acute-on-chronic liver injury Ersin Karatayli Received Received
  FRI-039 Autoimmune hepatitis-related cirrhosis: The importance of treatment response and the utility of Baveno VI criteria Laura Patricia Llovet Received Received
  SAT-039 The assessment of sarcopenia by quadriceps muscle ultrasound in patients with liver cirrhosis Stefania Gioia Received Received
  SAT-040 Is spleen stiffness the new frontier for non-invasive assessment of portal hypertension? Mauro Giuffrè Received Received
  LBP-040 Development of Oligonucleotide-Based miR-132 Antagonists for the Treatment of NASH Shoutian Zhu Received Received
  FRI-040 Imaging and clinical correlations of macro regenerative nodules in primary sclerosing cholangitis Beatrice Madrazo Received Received
  THU-041 Immune-metabolism disorder in progression of hepatitis B virus-related acute-on-chronic liver failure characterized by transcriptomics Jun Li Received Received
  FRI-041 Pharmacokinetics, safety, and tolerability of seladelpar in subjects with hepatic impairment Lily Mao Received Received
  SAT-041 The adjunct of sarcopenia with MHE increases the 1 year risk of developing OHE Rohit Gupta Received Received
  SAT-042 The stroop test is better at predicting the 6-month risk of developing overt hepatic encephalopathy compared to the PHES and CFF tests Rohit Gupta Received Received
  THU-042 Hypoxia aggravates acute on chronic hepatitis through MIR-210 mediated macrophage autophagy impairment Feifei Liu Received Received
  FRI-042 Prevalence and male/female ratio of autoimmune liver diseases are increasing over time in Japan: Hospital-based epidemiological study Kosuke Matsumoto Received Received
  FRI-043 Primary biliary cholangitis - Autoimmune hepatitis overlap syndrome: Characteristics and response to obeticholic acid in TARGET-PBC, a diverse, large United States real-world cohort Marlyn J. Mayo Received Received
  SAT-043 Is carvedilol better than propranolol in preventing variceal bleeding Muhammad Farooq Hanif Received Received
  THU-043 Declining mortality of cirrhotic patients requiring admission to intensive care units for serious infections: A bi-national cohort study Ammar Majeed Received Received
  SAT-044 Serum Myostatin in liver cirrhosis: A marker beyond malnutrition Rewan Hanno Received Received
  THU-044 Cystatin C as a predictive biomarker of ACLF development and mortality on the liver transplant waiting list Ezequiel Mauro Received Received
  FRI-045 Treatment of patients with primary biliary cholangitis with seladelpar for 52 weeks improves predicted transplant-free survival Carla Fiorella Murillo Perez Received Received
  SAT-045 Prevalence, type and risk factors of colonization by multidrug-resistant bacteria in a large series of patients with decompensated cirrhosis Maria Hernandez-Tejero Received Received
  SAT-046 Clinical impact of rectal colonization by multidrug-resistant bacteria in patients with decompensated cirrhosis Maria Hernandez-Tejero Received Received
  THU-046 Implementation of acute kidney injury criteria to patients with acute-on-chronic liver failure: Characteristics of effect on outcomes Laura Napoleone Received Received
  FRI-046 Raising awareness and messaging risk in patients with primary biliary cholangitis: The rapid Global PBC Screening Test Carla Fiorella Murillo Perez Received Received
  FRI-047 Metabolic syndrome delays biochemical remission in autoimmune hepatitis Richard Parker Received Received
  THU-047 Recalbration of the CLIF-C ACLF score after weighting by organ and by the presence of TIPS in patients with acute-on-chronic liver failure Enric Reverter Received Received
  SAT-047 Easy surveillance method without need of special equipment for muscle volume loss in patients with chronic liver disease Atsushi Hiraoka Received Received
  THU-048 Intermittent high-flux albumin dialysis with continuous venovenous hemodialysis for acute-on-chronic liver failure and acute kidney injury Jacek Rozga Received Received
  SAT-048 Changes in the intestinal microbiome during probiotic intervention in cirrhosis Angela Horvath Received Received
  FRI-048 Faecal calprotectin in PSC-IBD is a prognostic marker of cholangitis associated complications Polychronis Pavlidis Received Received
  THU-049 Impaired adaptive immunity is an early event in liver cirrhosis preceding acute-on-chronic liver failure Sabrina Rueschenbaum Received Received
  SAT-049 Lactate but not hemoglobin is a predictor for mortality in patients with liver cirrhosis and upper GI bleeding Thomas Horvatits Received Received
  FRI-049 Real world experience of obeticholic acid (Ocaliva) for the treatment of primary biliary cholangitis in the secondary care setting Anthony Pratt Received Received
  FRI-050 Antibodies to human beta-tubulin isotype 5 in autoimmune liver disorders - re-evaluation of their specificity and clinical relevance Beate Preuss Received Received
  THU-050 Genetic variants of innate immunity receptors are associated with mortality but not with bacterial infections in liver cirrhosis Jelte Schaapman Received Received
  SAT-050 Silymarins significantly improve long term survival in patients with liver cirrhosis regardless of MELD score Chien-Hao Huang Received Received
  SAT-051 The effects of portal vein thrombosis to patients with cirrhotic variceal bleeding underwent endoscopic treatment XIAOQUAN HUANG Received Received
  THU-051 Establishment of a new animal model for the acute-on-chronic liver failure Katharina Maria Schwarzkopf Received Received
  FRI-051 Pregnancy outcomes in women with autoimmune hepatitis Mussarat Rahim Received Received
  THU-052 Immunometabolic profiling of ascites from patients with acute-on-chronic liver failure reveals increased MerTK immunosuppressive myeloid cells and cell death markers with preferential lipid metabolism compared to cirrhosis without organ failure Arjuna Singanayagam Received Received
  SAT-052 Right psoas muscle area: Prognostic factor in patients with cirrhosis Child Pugh class C included on the waiting list for liver transplantation Speranta Iacob Received Received
  FRI-052 Long-term bezafibrate therapy does not prevent the progression of primary biliary cholangitis in patients with advanced disease Anna Reig Received Received
  FRI-053 Overlap of primary biliary cholangitis and autoimmune hepatitis. Natural history and prognosis in a large cohort of patients from Spain Anna Reig Received Received
  SAT-054 A higher prevalence of colorectal adenomatous polyps in patients with liver cirrhosis compared with non-cirrhotics Mohamed Saleh Ismail Received Received
  FRI-054 Immune-related hepatitis as an independent entity from autoimmune hepatitis: clinical, prognostic and therapeutic differences Mar Riveiro-Barciela Received Received
  FRI-055 Failure to normalize ALT and IgG in Autoimmune Hepatitis is associated with more advanced liver disease: Perspectives from a multi-ethnic Canadian AIH registry Surain Roberts Received Received
  SAT-055 Dobutamine counteracts the decrease in cardiac output after terlipressin in patients with cirrhosis and impaired kidney function but does not improve GFR: A randomised exploratory trial Mads Israelsen Received Received
  FRI-056 Obeticholic acid as adjunctive therapy in Primary Biliary Cholangitis: A review of early real-world experience Surain Roberts Received Received
  THU-056 Artificial liver support system improves short-term survival of patients with hepatitis B virus-related acute-on-chronic liver failure: A propensity-score matched analysis Jun Li Received Received
  SAT-056 Development of a novel prognostic model for cirrhotic patients with difficult-to-treat ascites and low MELD scores Peter Jepsen Received Received
  FRI-057 A review of primary biliary cholangitis practice in Wales: Time for specialist care Lavanya Shenbagaraj Received Received
  SAT-057 Proton pump inhibitors as a risk factor for hepatic encephalopathy and infections in cirrhotic patients: A clinical evidence Mafalda João Received Received
  FRI-058 Randomized controlled trial to compare efficacy of albumin dialysis using MARS versus new adsorbent recirculation for pruritus treatment Jan Stange Received Received
  SAT-058 In hepatic cirrhosis, the systemic levels of short chain fatty acids inversely correlate with the level of endotoxemia, and are negatively associated with an increased inflammatory response, impaired liver function and a higher HVPG Oriol Juanola Received Received
  THU-058 Gene profiling of toll-like recepter signaling pathways in patients with acute-on-chronic liver failure Ruihong Zhao Received Received
  FRI-059 Systematic review and meta-analysis of bezafibrate in combination with ursodeoxycholic acid in patients with treatment refractory primary biliary cirrhosis Ted Stoklosa Received Received
  SAT-059 Prevalence and clinical characteristics of malnutrition in cirrhosis according to new EASL practice guidelines Daewon Jun Received Received
  SAT-060 Prognostic effect of subcutaneous adipose tissue on survival outcome in patients with liver cirrhosis Seong Hee Kang Received Received
  FRI-060 Effects of the ileal bile acid transport inhibitor A4250 on pruritus and serum bile acids in patients with biliary atresia: phase 2 study results eva hortas Received Received
  FRI-061 Colorectal cancer, colectomy rates and inflammatory bowel disease activity following liver transplantation in primary sclerosing cholangitis: A systematic review and meta-analysis Tom Thomas Received Received
  SAT-061 Performance of Baveno criteria with shear-wave elastography in patients with compensated advanced chronic liver disease Seong Hee Kang Received Received
  FRI-062 Identifying research priorities in primary sclerosing cholangitis: Driving clinically meaningful change from the patients perspective Palak Trivedi Received Received
  THU-062 Exploring the immune environment in chronic hepatitis C associated fibrosis by examining the portal vein Rabab Oun Ali Anwar Ali Received Received
  SAT-062 Edema index measured by bioelectrical impedance analysis predicts ascites or acute kidney injury after liver resection for hepatocellular carcinoma Soon Sun Kim Received Received
  FRI-063 Low-dose prednisone increases the risk of adverse events in autoimmune hepatitis patients Floris Van Den Brand Received Received
  THU-063 Synergistic antifibrotic effect of rapamycin and zoledronic acid in advanced murine biliary fibrosis Misbah Aslam Received Received
  SAT-063 Third-generation cephalosporins are still useful as the empirical antibiotics for spontaneous bacterial peritonitis in Korea Sun Woong Kim Received Received
  THU-064 Identification of new epigenetic targets in hepatic fibrosis Marina Barcena-Varela Received Received
  SAT-064 The prognosis following bacterascites is as poor as spontaneous bacterial peritonitis Ji Jade King Received Received
  FRI-064 Systematic review and meta-analysis of risk factors for recurrent primary sclerosing cholangitis Iris Steenstraten Received Received
  SAT-065 Shear wave elastography for skeletal muscle: A novel approach to insulin resistance in cirrhosis Kazufumi Kobayashi Received Received
  FRI-065 The Amsterdam cholestatic complaints score is a valid patient reported outcome measure for cholestatic symptoms in PSC patients Kim Van Munster Received Received
  THU-065 Metformin reverses liver fibrosis via AMPK/PGC-1a mediated mitochondrial metabolic switch Jianye Cai Received Received
  THU-066 Association of apri index and elastography by shear wave elastography EIRA CERDA REYES Received Received
  SAT-066 Modified SAE tecnique provides a long last sustained hemodynamic response on splenic artery blood velocity in patients with cirrhosis and clinically significant portal hypertension Sergii Kozlov Received Received
  FRI-066 Rituximab therapy is effective for inducing remission in IgG4-RD hepatobiliary disease: A retrospective case series Danielle T Vannan Received Received
  FRI-067 Management of primary biliary cholangitis in the pre-obeticholic acid era, and the rate of non-response to ursodeoxycholic acid (UDCA), in a large real-world cohort of PBC patients in Italy: The CLEO-AIGO database Umberto Vespasiani-Gentilucci Received Received
  SAT-067 Prospective assessment of sarcopenia as a prognostic factor for survival in patients with liver cirrhosis Wolfgang Maximilian Kremer Received Received
  THU-068 Alcoholic and nonalcoholic fatty liver disease and liver-related mortality: A cohort study Yong Kyun Cho Received Received
  FRI-068 Quantitative biliary tree imaging by MRI: Evaluating new technology across patient cohorts with autoimmune liver disease gary woodward Received Received
  SAT-068 Presence of liver cirrhosis is the strongest negative predictor of survival for patients admitted to intensive care unit Alica Kubesch Received Received
  SAT-069 Interleukin 6: A marker for hepatic encephalopathy Christian Labenz Received Received
  FRI-069 Quantitative MRCP imaging: Preliminary observations in a cohort of paediatric patients with liver and biliary diseases gary woodward Received Received
  THU-069 Human adipose derived stem cells exhibit enhanced liver regeneration in liver fibrosis model by controlled releasing hepatocyte growth factor Ja Sung Choi Received Received
  FRI-070 Long-term clinical outcomes in patients with autoimmune hepatitis according to treatment response in Asian country Sun Yoo Received Received
  THU-070 The nuclear factor TCF20 regulates the severity of liver fibrosis in mice Bernat Cordoba-Jover Received Received
  SAT-070 A clinical pathway to manage patients with decompensated cirrhosis: Assessing the level of compliance with evidence based guidelines Abdulnasser Lafta Received Received
  SAT-071 Insulin resistance in cirrhotic patients: results from a large prospective study Nicolas Lanthier Received Received
  THU-071 Matrix modulation in chronic liver injury and resolution Marika Crescenzi Received Received
  FRI-071 AMA-positives without PBC and healthy subjects have similar bile acid profiles but are different from PBC patients Stephan Zandanell Received Received
  THU-072 N-ras protects against experimental liver fibrosis by maintaining hepatocyte homeostasis Francisco Javier Cubero Received Received
  FRI-072 Alteration of glucocorticoid metabolism in patients with cholestasis Gernot Zollner Received Received
  THU-073 The use of APRI and FIB-4 scores versus transient elastography for the assessment of liver fibrosis stage in patients with chronic hepatitis C: Is it possible to reduce the need for elastography? Melanie Deutsch Received Received
  SAT-073 Micronutrient deficiencies in patients with decompensated cirrhosis Gemma Llibre Nieto Received Received
  SAT-074 Prevalence and risk factors of colonization by multidrug resistant bacteria in cirrhotic patients admitted to the intensive care unit in a Spanish tertiary hospital Sara Lorente Received Received
  THU-074 Anti-fibrotic effect of dimethyl fumarate on rat liver fibrosis induced by thioacetamide: Role of NF-kappa B, NLRP3, Nrf2 and autophagy Durgesh Kumar Dwivedi Received Received
  THU-075 2d- shear wave elastography for the spleen stiffness evaluation: A noninvasive marker for predicting high risk varices in patients with compensated liver cirrhosis Fofiu Renata Received Received
  FRI-076 On the role of inflammation in acute paracetamol injury Saleh Alabbas Received Received
  SAT-076 Long term palliative abdominal drains versus large volume paracentesis in refractory ascites due to cirrhosis: a multi-centre feasibility randomised controlled trial (the REDUCe Study) Lucia Macken Received Received
  THU-077 Fibro-protective molecular and cellular mechanisms emerge during resolution from thioacetamide-induced fibrosis Francis Gratte Received Received
  FRI-077 Influence of drug categorization according to labelling information in the phenotypic presentation of drug-induced liver injury (DILI): An analysis in the Spanish DILI registry Laura Sanz-Villanueva Received Received
  SAT-077 Intraperitoneal activation of blood coagulation via tissue factor-exposing extracellular vesicles in patients with advanced chronic liver disease Mattias Mandorfer Received Received
  FRI-078 Serious liver injury induced by nimesulide: An international collaboration reporting 57 cases Fernando Bessone Received Received
  SAT-078 Characterizing compensated cirrhosis patients with potential etiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Findings from large Italian administrative databases Jie Ting Received Received
  THU-078 PBI-4050 inhibits hepatic stellate cell activation, restores autophagy, and reduces CCl4-induced liver fibrosis Brigitte Grouix Received Received
  THU-079 Study of anti-fibrotic activity of human umbilical-cord tissue-derived mesenchymal stromal cells during fibrogenesis or resolution in murine models of liver fibrosis Debashis Haldar Received Received
  SAT-079 Respiratory infection in patients with cirrhosis and acute variceal bleeding on antibiotic prophylaxis: A multicenter observational study of 2138 patients Javier Martinez Received Received
  FRI-079 HLA B14:01 is associated with Trimethoprim-sulfamethoxazole induced liver injury Naga Chalasani Received Received
  FRI-080 Herbal medicines induces severe liver injury than western medications: A nationwide multicenter retrospective research Jun Chen Received Received
  FRI-081 Characterisation of severe liver injury induced by immune checkpoint inhibitors Yana Davidov Received Received
  THU-081 Saracatinib, a Src family kinase inhibitor, decreases liver fibrosis Byoung Kuk Jang Received Received
  THU-082 Thymosin beta 4 is a potential regulator of radiation-induced liver fibrosis Jieun Kim Received Received
  FRI-082 Super stealth immunoliposomes as a strategy to overcome liposome-induced liver toxicity Sara De Martin Received Received
  SAT-083 Simple non-invasive surrogates of portal hypertension predict clinical decompensation in overweight/obses patientes with cACLD Yuly Paulin Mendoza Received Received
  THU-083 Predicting advanced liver fibrosis using deep learning based biopsy image analysis Sergey Klimov Received Received
  FRI-083 Impact of acetaminophen on acute liver failure of unknown cause Decoster Claire Received Received
  THU-084 A comparative study of anti-Fibrotic therapeutics using aptamer-based quantitative proteomics in a rat model of nonalcoholic steatohepatitis cirrhosis Smitha Krishnan Received Received
  FRI-084 Targeting Toll-Like Receptor 4 signalling with TAK-242: A novel therapy for acute liver failure Cornelius Engelmann Received Received
  SAT-084 Validation of hand grip strength as a nutritional assessment tool for patients with advanced liver fibrosis Topan Mirabela-Madalina Received Received
  FRI-085 Development and validation of a novel non-invasive model to predict drug-induced liver injury recurrence Chun-Yan Wang Received Received
  SAT-085 Selective improvement by rifaximin of changes in the inmunophenotype in patients who improve minimal hepatic encephalopathy Carmina Montoliu Received Received
  THU-086 Clinical study on plasma golgi protein 73 and the progression of viral hepatitis C-induced hepatic fibrosis Liu Lingdi Received Received
  FRI-086 Stem cell treatment on acute liver failure model using semipermeable Poly Lactic-co-Glycolic Acid membrane pouch Bo-Kyeong Kang Received Received
  SAT-086 Opioid use is common among non-surgical inpatients with cirrhosis and is associated with increased length of stay and persistent use post-discharge Andrew Moon Received Received
  THU-087 A 3-dimensional dynamic model to explore the immunomodulatory properties of the extracellular matrix and their implications in liver fibrosis Claire Mcquitty Received Received
  FRI-087 The good use of paracetamol: prospective assessment of the knowledge of prescribers (practitioners, residents), pharmacists, care providers (nurses, others) and students in an university medical center Dominique larrey Received Received
  SAT-087 Screening endoscopy in patients with advanced chronic liver disease beyond portal hypertension: Higher prevalence of upper gastrointestinal neoplasia in comparison to a healthy screening population Rui Morais Received Received
  FRI-088 The good use of non steroidal anti-inflammatory drugs (nsaids): prospective assessment of the knowledge of prescribers (practitioners, residents), care providers (nurses), pharmacists and students in an university medical center Dominique Larrey Received Received
  THU-088 Serum markers of interstitial matrix formation (PRO-C3) and basement membrane remodeling (PRO-C4 and C4M) predict recurrence of fibrosis and survival in post-liver transplanted patients Mette Juul Nielsen Received Received
  SAT-088 Sarcopenia and Myosteatosis are associated with minimal and overt hepatic encephalopathy in patients with liver cirrhosis SILVIA NARDELLI Received Received
  FRI-089 Genetic deletion of Keap in hepatocytes improves liver damage, but triggers hepatitis in an Nrf2-dependent manner, in experimental toxic liver injury LAURA MORÁN Received Received
  SAT-089 Evaluating the impact of non-ive beta-blocker use in decompensated cirrhosis based on setting of patient care Rooshi Nathwani Received Received
  THU-089 Characterization of CDAA mouse model for non-alcoholic steatohepatitis at various time-points Larissa Pfisterer Received Received
  FRI-090 Enhanced ASPP2 improves liver injury by way of an inflammatory immune regulatory mechanism in acute liver failure Feng Ren Received Received
  THU-090 Non-invasive fibrosis scores (APRI, FIB4 index, BARD): Useful tools for evaluating fatty liver disease Alina Popescu Received Received
  SAT-090 Location of onset of acute kidney injury in cirrhosis affects survival Janardhan Navaratnam Received Received
  SAT-091 The collagen hormone Endotrophin, a biomarker of type VI collagen formation - is associated with severe decompensation and predicts transplant-free survival in patients with trans-jugular intrahepatic portosystemic shunt Mette Juul Nielsen Received Received
  FRI-091 HGF protector effect in intrahepatic cholestasis Elsy Soraya Salas Silva Received Received
  THU-091 Acalcemic vitamin D analogues show antifibrotic effects in vitro while paricalcitol prevents progression of established fibrosis in the CCl4 mouse-model Florian Reiter Received Received
  FRI-092 Metamizole as a leading cause of drug-induced liver injury Marcial Sebode Received Received
  SAT-092 The efficacy and safety of rifaximin-a: a 2-year observational study of overt hepatic encephalopathy Rosalie Oey Received Received
  THU-092 Role of endothelial mitophagy during endothelial dysfunction and liver fibrosis Maria Ruart Received Received
  THU-093 The calpain inhibitor, BLD-2660, has robust anti-fibrotic activity in a rat model of nonalcoholic steatohepatitis Mozhdeh Sojoodi Received Received
  FRI-093 Low volume plasma exchange in patients with acute liver failure: A real world study Mohammed Sheikh Received Received
  SAT-093 Underutilization of hospice in inpatients with cirrhosis: The NACSELD experience Jacqueline OLeary Received Received
  FRI-094 Targeting NEDDylation protects liver from acute drug-induced damage Simón Jorge Received Received
  THU-094 Simple prediction score to predict fibrosis in type 2 diabetes mellitus patients Ioan Sporea Received Received
  SAT-094 Effects of branched-chain amino acids on the progression of advanced liver disease: A Korean nationwide, multicenter, prospective, observational, cohort study Jung Gil Park Received Received
  THU-095 Short and long-term evaluation of liver fibrosis and outcomes in patients with chronic hepatitis C after INF-free antiviral treatment Cristina Stasi Received Received
  FRI-095 The overweight role in the occurrence of hepatotoxic reactions during chemotherapy of chronic lymphocytic leukaemia Igor Skrypnyk Received Received
  THU-096 Development and validation of true serum biomarkers of liver fibrogenesis ans fibrolysis Rambabu Surabattula Received Received
  SAT-096 Large spontaneous portosystemic shunt (SPSS) area is associated with hepatic encephalopathy and predicts mortality in liver cirrhosis Michael Praktiknjo Received Received
  FRI-096 Technetium-99m-GSA within the first 3d after admission as an early predictor of outcome in severe acute liver injury Yuji Suzuki Received Received
  THU-097 Serum infrared spectral profile is predictive of the degree of hepatic fibrosis in chronic hepatitis C patients Gérard Thiéfin Received Received
  SAT-097 Non-invasive estimation of intravascular volume status in cirrhosis by dynamic size and collapsibility Indices of the inferior vena cava using bedside echocardiography Madhumita Premkumar Received Received
  FRI-097 PBI-4050 treatment decreases sepsis-induced liver injury in mice Jean-Francois Thibodeau Received Received
  FRI-098 Targeting cholesterol with atorvastatin protects against valproic acid-induced sensitization to acetaminophen hepatotoxicity Sandra Torres Received Received
  THU-098 Changes in liver stiffness measurements following DAA treatment among HIV/HCV-coinfected individuals: Does HIV contribute to liver disease after HCV cure? Daniela Van Santen Received Received
  FRI-099 PD-1 monocytes and macrophages contribute to impaired microbial clearance following acute liver failure Evangelos Triantafyllou Received Received
  THU-099 Collagen is not just collagen: Differential matrix expression induced by TgF-beta and PDGFs Ida Villesen Received Received
  SAT-100 Expanding the Baveno VI criteria for the screening of varices in advanced liver disease patients Iulia Ratiu Received Received
  FRI-100 Protective effects of glutathione and lipoic acid against cadmium-induced oxidative stress in rats liver Andrej Veljkovic Received Received
  THU-100 FGL2 regulates liverfibrosis progression and reversal by promoting profibrotic infiltrating macrophages maintenance Xiaoyang Wan Received Received
  FRI-101 FGL2 deficiency resists viral fulminant hepatitis through abrogating inflammatory macrophage activation Xiaoyang Wan Received Received
  THU-101 Artery density in human liver: A valuable measure for staging of chronic liver disease Ian Wanless Received Received
  SAT-101 Detrimental effect of proton pump inhibitors in cirrhosis depends on common genetic variation Matthias Reichert Received Received
  FRI-102 Metabolomic and inflammatory mediator based biomarkers analysis for identification of severe drug induced liver injury Zhongyang Xie Received Received
  SAT-102 Cirrhotic patients with vitamin d deficiency fail to respond to oral replacement therapy Freya Rhodes Received Received
  SAT-103 Bone disease does not correlate with severity of liver disease in cirrhosis Freya Rhodes Received Received
  FRI-103 A sublethal dose of acetaminophen suffices to induce the unfolded protein response in hepatocytes through an IRE1alpha-JNK1-XBP1s-dependent mechanism Hui Ye Received Received
  SAT-104 Factors associated with renal replacement therapy and mortality following first episode of acute knidney injury in inpatients with cirrhosis Susana G. Rodrigues Received Received
  SAT-105 Rising economic burden following the diagnosis of compensated cirrhosis among hospitalized patients with Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis in Spain Nandita Kachru Received Received
  THU-105 Modulation of G protein alpha inhibiting activity polypeptide 2 in hepatocytes regulate liver fibrosis Qinggong Yuan Received Received
  SAT-106 Prevalence and survival of fungal peritonitis in decompensated cirrhosis Noam Roth Received Received
  FRI-106 Combining endozepine-4 and blood ammonia: Does it improve the diagnosis of hepatic encephalopathy in patients with liver cirrhosis? Mohamed Abaza Received Received
  FRI-107 Emerging role of taurine conjugated bile acids in the gut liver axis and on hepatic bile acid receptors in chronic hepatitis C Rabab Oun Ali Anwar Ali Received Received
  SAT-107 Effect of a multifactorial intervention (non-alcoholic beer, diet and exercise) on endothelial function, nutritional status and quality of life in patients with cirrhosis Astrid Ruiz-Margain Received Received
  SAT-108 Sarcopenia and nutritional status predict mortality in patients with cirrhosis undergoing liver transplant assessment John Ryan Received Received
  FRI-108 Gut-derived GABA is strongly linked with cognitive impairment in cirrhosis JASMOHAN BAJAJ Received Received
  FRI-109 Increased plasma leukotriene B4 in decompensated cirrhosis associates with disease progression and leads to increased skin window neutrophil infiltration Natalia Becares Received Received
  SAT-109 Spontaneous bacterial peritonitis: Will the diagnostic follow-up paracentesis be essential in approaching these patients? Ana Santos Received Received
  SAT-110 Impact of rifaximin monotherapy or rifamixin plus lactulose on markers of inflammation in patients with cirrhosis and a history of hepatic encephalopathy Arun Sanyal Received Received
  FRI-110 A nutraceutical supplement rich in docosahexaenoic acid improves portal hypertension in a pre-clinical model of chronic liver disease Zoe Boyer-Diaz Received Received
  SAT-111 Procalcitonin level is a prognostic marker in patients with liver cirrhosis Sho Sato Received Received
  FRI-111 Albumin modulates endosomal TLR9 signaling in human peripheral leukocytes: A mechanism for its anti-inflammatory role in ACLF Mireia Casulleras Received Received
  THU-111 High efficacy and safety of the combination HCV regimen elbasvir and grazoprevir for 8 weeks in treatment-naive non-severe fibrosis HCVGT1b-infected patients: Final results of the STREAGER study Frederic Faure Received Received
  THU-112 Real-world health care resource utilization and quality of life with G/P treatment: A pooled analysis from post-marketing observational studies Hannah Welz Received Received
  SAT-112 Each additional infection significantly increases mortality in patients with decompensated liver cirrhosis Marie Schultalbers Received Received
  FRI-112 Prediction of treatment failures in a multicentre feasibility trial using human albumin solution to prevent infection in acute decompensation of liver cirrhosis Louise China Received Received
  SAT-113 Non-invasive assessment of HVPG with quantitative MRI measures of liver T1 and superior mesenteric artery velocity at 3T Robert Scott Received Received
  THU-113 Comparison between safety and efficacy of two treatment regimens for pediatric patients with chronic hepatitis C virus: Sofosbuvir/ledipasvir versus sofosbuvir/daclatasvir regimen mohamed ahmed Received Received
  FRI-113 Matrix stiffness modulates the phenotype of hepatic cells in cirrhosis and modifies the sinusoidal effects of statins Sergi Guixé-Muntet Received Received
  SAT-114 Impact of farnesoid X receptor polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension Georg Semmler Received Received
  THU-114 A comparison of currently available direct acting antiviral HCV therapy in Canada: On the path to elimination Arshia Alimohammadi Received Received
  FRI-115 Toll-like receptor 4: A novel therapeutic target for the treatment of hyperammonemia Annarein J.C. Kerbert Received Received
  SAT-115 Fondaparinux vs low molecular weight heparin in the treatment of non malignant portal vein thrombosis in patients with cirrhosis Alberto Zanetto Received Received
  THU-115 Effects of health-related quality of life of interferon-free antiviral therapy for chronic hepatitis C infection - Results from the GermanhHepatitis C-Registry (DHC-R) Yvonne Serfert Received Received
  FRI-116 Capturing the complexities of the immune system in patients with advanced cirrhosis using a whole blood culture system reveals a robust inflammatory response to endotoxin stimulation Victoria Kronsten Received Received
  THU-116 Effectiveness of the salvage therapy sofosbuvir-velpatasvir-voxilaprevir (SOF-VEL-VOX) in chronic hepatitis C: Clinical practice experience from the TRIO Network NICOLE WICK Received Received
  SAT-116 Development and validation of a novel model for outcome in patients with cirrhosis and acute variceal bleeding Dr Shalimar Received Received
  SAT-117 Enhanced liver fibrosis score is an accurate non-invasive predictor of clinically significant and high-risk portal hypertension Benedikt Simbrunner Received Received
  THU-117 Evaluation of risk factors associated with failure to a first-line NS5A-containing regimen in HCV-infected patients naive to direct acting antivirals: Particular focus on natural resistance Silvia Barbaliscia Received Received
  FRI-117 The gain of function mutation of SerpinB3 (SCCA-PD) is associated with the severity of portal hypertension and complications onset in patients with advanced liver disease Andrea Martini Received Received
  SAT-118 Estimating proportion of cirrhosis and hepatocellular carcinoma attributable to hepatitis B and C in clinical centres in Sofia (Bulgaria) and Lisbon (Portugal): Results from a European pilot Marieta Simonova Received Received
  THU-118 Factors associated with hepatitis C treatment uptake among people who inject drugs in a population based data linkage study Sofia Bartlett Received Received
  FRI-118 Decreased cognitive performance is associated with reduced resting state connectivity and gray matter atrophy in patients with minimal hepatic encephalopathy Carmina Montoliu Received Received
  FRI-119 Distinct salivary microbiome profile in patients with decompensated cirrhosis Theodora Oikonomou Received Received
  SAT-119 Comparison of liver frailty index at admission and 30 days after discharge from hospital in patients with advanced chronic liver disease Lubomir Skladany Received Received
  THU-119 Direct-acting antiviral regimens without protease inhibitors may help maintain a healthy lipid profile after hepatitis C eradication Javier Fuentes Received Received
  FRI-120 Structural liver disease rather than portal hypertension is the predominant factor for hepatic macrophage activation in patients with cirrhosis, portal vein thrombosis and idiopathic portal hypertension Nikolaj Worm rntoft Received Received
  THU-120 Hepatitis C In children: Clinical profile and outcomes In the era of directly-acting antivirals in a tertiary centre in North India Vybhav Gummadi Received Received
  FRI-121 Portal hypertension in nodular regenerative hyperplasia is caused by vascular remodeling with extensive regression of portal vein branches Christian Perez Shibayama Received Received
  SAT-121 Predicting sarcopenia in patients with cirrhosis based on clinical and laboratory parameters using machine learning Guido Stirnimann Received Received
  THU-121 Real world outcomes from NS5a treatment failures undergoing therapy with sofosbuvir/velpatasvir/voxilaprevir and sofosbuvir/glecaprevir/pibrentasvir Alison Boyle Received Received
  THU-122 Sofosbuvir/velpatasvir /- ribavirin for retreatment of patients with chronic hepatitis C virus infection and advanced fibrosis failing to a previous DAA combination regimen Giuseppina Brancaccio Received Received
  SAT-122 Cirrhotic cardiomyopathy: An observational study pre-liver transplant Mohsan Subhani Received Received
  SAT-123 Serum Mac-2 binding protein glycosylation isomer and handgrip strength correlate with serum myostatin level in chronic liver disease Tomoyuki Suehiro Received Received
  FRI-123 Transcriptomic and functional analysis of Kupffer cells in patients with cirrhosis reveals a tumour associated macrophages profile and an impaired immune response that are associated with increased risk of infections ELISA POSE Received Received
  THU-123 No effect of alcohol consumption or dependence on treatment outcome in chronic hepatitis C patients treated with Elbasvir/Grazoprevir in a real-world setting Jean-Pierre Bronowicki Received Received
  FRI-124 Increased prevalence of low-frequency and rare NOD2 variants in patients with liver cirrhosis Matthias Reichert Received Received
  SAT-124 Microbiological culture yield from ascitic fluid and changing antimicrobial sensitivities over time Rachael Swann Received Received
  THU-124 Efficacy and safety of glecaprevir/pibrentasvir for the pangenotypic treatment of chronic hepatitis C in former intravenous drug users: Subanalysis from a Spanish real-world cohort (Hepa-C) Jose A. Carrión Received Received
  SAT-125 Animal naming test is simple and reliable for diagnosis of minimal hepatic encephalopathy and prediction of development of overt hepatic encephalopathy in patients with cirrhosis Sunil Taneja Received Received
  THU-125 High real-world effectiveness of elbasvir/grazoprevir in PWID on opioid substitution therapy with HCV genotype 1 infection: Results from the German hepatitis C registry (DHC-R) Stefan Christensen Received Received
  FRI-125 The phase angle determined by bioelectrical impedance is a predictive factor of hospitalization, falls and mortality in patients with cirrhosis Eva Roman Received Received
  FRI-126 Innovative potential biomarkers in spontaneous bacterial peritonitis from ascitic fluid Sophia Scherm Received Received
  THU-126 HCV treatment outcomes among current and remote injection drug users: Real- life data Tianna Magel Received Received
  SAT-126 Minimal hepatic encephalopathy: Proper diagnosis for a better quality of life Vlad Taru Received Received
  FRI-127 Measuring dynamics of portal pressure and vital parameters in conscious rats using real-time telemetry Philipp Knigshofer Received Received
  SAT-127 The clinical course of recurrent versus refractory ascites in outpatients with cirrhosis Marta Tonon Received Received
  THU-127 Clinical Practice experience with pan genotypic therapies glecaprevir-pibrentasvir and sofosbuvir-velpatasvir in the TRIO Network NICOLE WICK Received Received
  SAT-128 The natural history of acute kidney disease in patients with cirrhosis Marta Tonon Received Received
  FRI-128 Mesenchymal stem cells cultured in hypoxic conditions had multi-directional effects on mice with liver cirrhosis through prostaglandin E2 and miR210 production Atsunori Tsuchiya Received Received
  THU-128 Renal safety in 3,264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study Roberta DAmbrosio Received Received
  THU-129 New antiviral therapy and the quality of life in patients with HCV infection Claudia Monica Danilescu Received Received
  SAT-129 Type 2 diabetes in patients with liver cirrhosis: prevalence, associated factors and influence on survival Maria Torner Simó Received Received
  FRI-129 A defect in the Nrf2/HO-1 pathway and Nox2 activation results in regulatory T cell mitochondrial dysfunction in alcohol related cirrhosis Trishan Vaikunthanathan Received Received
  THU-130 Management strategies for drug drug interactions between direct oral anticoagulants and hepatitis C directly acting agents: A multi-centre review Katherine Davidson Received Received
  SAT-130 Incidence and outcome of portal vein thrombosis in 817 HBV and HCV compensated cirrhotic patients under antiviral treatment: a single center longitudinal study Giulia Tosetti Received Received
  FRI-130 Changes in the extracellular matrix of the heart and the liver assessed by MRI with T1-mapping are closely linked in cirrhosis: Is inflammation the shared pathway? Signe Wiese Received Received
  SAT-131 The impact of sustained virological response on the criteria used to rule out high risk esophageal varices in HCV-related compensated advanced chronic liver disease Giulia Tosetti Received Received
  FRI-131 Impact of HBsAg level on cellular immune responses in HBeAg negative patients with chronic hepatitis B virus infection Elmira Aliabadi Received Received
  THU-131 Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir for retreatment of chronic hepatitis C patients with a previous failure to direct-acting antivirals: A real-life study from the NAVIGATORE Lombardia and Veneto Networks Elisabetta Degasperi Received Received
  SAT-132 Incidence and prognostic factors of de novo development /worsening of esophageal varices in HCV-related compensated advanced chronic liver disease after sustained virological response achieved by direct antiviral agents Giulia Tosetti Received Received
  FRI-132 In vitro modulation by TLR8 agonist GS-9688 of multiple regulatory cell types in patients with chronic hepatitis B Oliver E Amin Received Received
  THU-132 Decentralised care with generic direct antivirals is effective in the management of patients with hepatitis C in a public health care setting: The Punjab model Radha Krishan Dhiman Received Received
  SAT-133 2D-Shear-Wave elastography predicts survival in advanced chronic liver disease Jonel Trebicka Received Received
  THU-133 Resistance-guided retreatment of HCV infected patients with a previous failure to an NS5A inhibitor-containing regimen: Italian real life experience Velia Chiara Di Maio Received Received
  FRI-133 HCV neutralizing antibody responses in natural infections mapped by metric multi-dimensional scaling reveals new insights into HCV antigenicity and broadly neutralzing antibodies Dorothea Bankwitz Received Received
  FRI-134 Comparative analysis of intrahepatic and peripheral chemokine responses in chronic hepatitis B, C and D in vivo Jan-Hendrik Bockmann Received Received
  SAT-134 Hypercoagulopathy risk factors in liver cirrhosis due to non-alcoholic steatohepatitis and clinical manifestations of hypercoagulation during 5 years Nataliya Virstyuk Received Received
  THU-134 Clinical and virological characteristics of patients with chronic hepatitis C and failure to voxilaprevir/velpatasvir/sofosbuvir treatment Julia Dietz Received Received
  THU-135 Real-world HCV treatment in HCV-HIV coinfected population: Data from the TRIO network NICOLE WICK Received Received
  SAT-135 Splenomegaly status does not impact the efficacy of avatrombopag in increasing platelet counts and reducing platelet transfusions or rescue procedures for bleeding in chronic liver disease patients with thrombocytopenia Michael Vredenburg Received Received
  FRI-135 Toll-like receptor signalling induces changes in the Hippo signalling pathway that counter regulates innate immune responses in hepatocytes Ruth Broering Received Received
  SAT-136 Hepatocellular carcinoma does not impact the efficacy of avatrombopag in increasing platelet counts and reducing platelet transfusions or rescue procedures for bleeding in chronic liver disease patients with thrombocytopenia Michael Vredenburg Received Received
  THU-136 Ledipasvir/sofosbuvir for 8 weeks cures genotype 4 chronic hepatitis C in non-cirrhotic children and adolescents Manal Hamdy El-Sayed Received Received
  FRI-136 Hepatitis B core antibody (anti-HBc) mirrors activation of hepatitis B virus-specific immune responses and exhibits direct effect on hepatitis B virus control Chengcong Chen Received Received
  FRI-137 l-carnitine impedes hepatitis B surface antigen loss through immunosuppressive effect in chronic hepatitis B virus infection Shuqin Gu Received Received
  THU-137 DAA therapy in women of child bearing age: Accidental conception during therapy and pregnancy outcome Manal Hamdy El-Sayed Received Received
  SAT-137 Adverse drug reactions in patients with cirrhosis: analysis of spontaneous reports from the Dutch Pharmacovigilance Centre Lareb Rianne Weersink Received Received
  THU-138 High efficacy and improvement in CPT class with sofosbuvir/velpatasvir plus ribavirin for 12 weeks in patients with CPT C decompensated cirrhosis eva hortas Received Received
  FRI-138 HBVcore- versus HBVpolymerase-specific CD8 T cells differ in chronically HBV-infected patients Kathrin Heim Received Received
  SAT-138 Cirrhotic cardiomyopathy: A 2-year longitudinal follow-up study using advanced cardiac imaging Signe Wiese Received Received
  SAT-139 Predictive factors for the development of acute-on-chronic liver failure in a North American cohort of hospitalized patients with cirrhosis and decompensation Florence Wong Received Received
  FRI-139 Intrahepatic transcriptional profiling of chronic hepatitis B patients during interferon-alpha treatment Minhui Dong Received Received
  THU-139 Real world experience of chronic hepatitis C retreatment with genotype specific regimens in non-responders to previous interferon-free therapy Robert Flisiak Received Received
  THU-140 Characteristics of patients and effectiveness of chronic hepatitis C treatment during the initial 4 years of access to interferon-free therapy Robert Flisiak Received Received
  SAT-140 The natural history of stages 2 and 3 acute kidney injury in hospitalized patients with decompensated cirrhosis and ascites Florence Wong Received Received
  FRI-140 Chemokine (C-X-C motif) ligand 13-mediated recruitment of intrahepatic chemokine (C-X-C motif) receptor 5CD8 t cells contribute to viral control in chronic hepatitis B patients and hepatitis B virus mouse model Yongyin Li Received Received
  SAT-141 The diagnosis of hepatorenal syndrome: How much does use of the 2015 revised consensus recommendations affect earlier treatment and serum creatinine at treatment start? Florence Wong Received Received
  THU-141 Efficacy and safety of elbasvir/grazoprevir in a large real-life cohort of HCV-infected patients Martina Gambato Received Received
  FRI-141 Rapid decrease in titer and breath of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved sustained virological response Isidoro Martínez Received Received
  SAT-142 Incidence of hepatocellular carcinoma and cirrhotic complications in patients with psychiatric illness: A territory-wide cohort study Vincent Wai-Sun Wong Received Received
  THU-142 Sofosbuvir velpatasvir voxilaprevir in DAA failure patients with cirrhosis: Final results of the French compassionate use program Christophe Hezode Received Received
  FRI-142 Interferon regulatory factor 5 and soluble fibrinogen-like protein 2 in hepatitis B virus related liver diseases Xuan Hoan Nghiem Received Received
  THU-143 High effectiveness of elbasvir/grazoprevir treatment in patients with HCV genotype 1a infection in German real-world: Results from the German hepatitis C registry (DHC-R) Holger Hinrichsen Received Received
  FRI-143 Liver-resident HBV-specific CD8 T cells are long-lived and can be replenished by allogenic responses following transplantation Laura J Pallett Received Received
  FRI-144 Performance study of new geenius HCV supplemental assay Anthony Palvadeau Received Received
  THU-145 High real-world effectiveness of elbasvir/grazoprevir in a HCV genotype 1 population with a migration background and predominant subtype 1b infection: Results from the German hepatitis C registry (DHC-R) Dietrich Hppe Received Received
  FRI-145 Direct acting antiviral treatment decreases inhibitoryTIM-3 immune checkpoint receptor expression on NKcells in patients with chronic HCV Gabriella Par Received Received
  SAT-146 Assessing liver function in patients who underwent balloon occluded retrograde transvenous obliteration Thomas Xu Received Received
  THU-146 LDV/SOF/RBV is an effective first-line DAA regimen as well as re-treatment option for RF1_2k/1b patients within Georgian national hepatitis C elimination program Marika Karchava Received Received
  FRI-146 Long-term nucleos(t)ide-analogue treatment in chronic hepatitis B eAg(-) together with a low level of HBsAg leads to a non-exhausted HBV-specific T CD8 response Julia Peña Asensio Received Received
  SAT-147 Interaction between renal and liver impairment on the risk of lactic acidosis in diabetic patients with chronic hepatitis B-related cirrhosis Terry CF Yip Received Received
  FRI-147 Gradual restoration of HCV-specific CD8 T cell frequency but persistence of altered phenotype in cirrhotic HCV-infected patients after successful direct-acting antiviral therapy Elena Perpiñán Received Received
  THU-148 Variability of ed extracellular matrix proteins concentrations in HCV infected patients treated with sofosbuvir and ledipasvir Krzysztof Tomasiewicz Received Received
  FRI-148 Downregulation of innate and adaptive gene expression alleviated by host protein osteopontin in an immunocompetent model of hepatitis B infection Sandra Phillips Received Received
  SAT-148 The role of kidney biomarkers in cirrhotic patients with acute kidney injury: interim analysis of multicenter, prospective cohort study Jeong-Ju Yoo Received Received
  SAT-149 Optimal ion of sedative drug during endoscopy in cirrhotic patients to avoid minimal encephalopathy Jeong-Ju Yoo Received Received
  FRI-149 Comprehensive transcriptome analysis of liver biopsies from chronically infected HBV patients Ricardo Ramirez Received Received
  FRI-150 Association of the immunodominant HLA-B35:01 restricted CD8 T cell epitope with clustered viral evolution in HBV polymerase Elahe Salimi Alizei Received Received
  SAT-150 Validation of Korean stroop test in the screening of minimal hepatic encephalopathy Eileen Yoon Received Received
  THU-150 Factors associated with treatment failure with SOFRBV in patients with genotype 2 chronic hepatitis C and consideration of retreatment with GLEPIB in patients not responding to SOFRBV Atsunori Kusakabe Received Received
  SAT-151 What are the predictors of impairment of patient-reported outcome in non-alcoholic steatohepatitis? Zobair Younossi Received Received
  THU-151 Real-world effectiveness and safety of glecaprevir plus pibrentasvir in HCV: A multi-country analysis of postmarketing observational studies Hannah Welz Received Received
  FRI-151 Characterization of regulatory T cells and the role of PD-1 and TNF-alpha in spontaneous hepatitis B surface antigen seroclearance in chronic hepatitis B Fen Liu Received Received
  SAT-152 Prediction of nosocomial acute-on-chronic liver failure in patients with cirrhosis admitted to hospital with acute decompensation Giacomo Zaccherini Received Received
  FRI-153 Potent hepatitis B core-specific B cell responses associate with clinical parameters in untreated and virally suppressed chronic HBV patients Thomas Vanwolleghem Received Received
  SAT-153 A systematic review and meta-analysis of the efficacy of magnetic resonance spectroscopy in the diagnosis of hepatic encephalopathy Georgia Zeng Received Received
  THU-153 Is sofosbuvir-based regimen safe and effective in hepatitis C virus-infected patients with stage 4-5 chronic kidney disease? A systematic review and meta-analysis Mingshu Li Received Received
  FRI-154 Augmentation of HBV-specific CD4 T cell responses via combined OX40 stimulation and PD-L1 blockade Katharina Wild Received Received
  SAT-154 Acute hemodynamic response to I.V propranolol during hepatic hemodynamic study in 26 cirrhotic patients with portal hypertention and nonbleeding esophageal varices. Correlation with esophageal bleeding and survival Eli Zuckerman Received Received
  THU-154 Low rate of hepatitis B reactivation among patients with chronic hepatitis C during direct acting antiviral therapy Seng Liem Received Received
  THU-155 Polymeric, metallic nanoparticles, and curcumin as inhibitors of hepatitis C virus genotype 4a replication in vitro samah khalil Received Received
  THU-156 Real world outcomes for Genotype 3 patients treated with glecaprevir/pibrentasvir: Real world outcomes from an uned cohort Fiona Marra Received Received
  FRI-157 Novel HBV capsid assembly modulator inhibits pregenomic RNA encapsidation by accelerating capsid assembly kinetics and disrupting core protein dephosphorylation Leda Bassit Received Received
  THU-157 Shortened duration pan-genotypic therapy with glecaprevir-pibrentasvir for six weeks among people with acute and recent HCV infection Marianne Martinello Received Received
  THU-158 High efficacy of sofosbuvir and velpatasvir regardless of patients clinical characteristics Vitor Hugo Martins Received Received
  THU-159 Real-world efficacy of elvasvir and grazoprevir for hepatitis C virus (genotype 1): A nationwide, multicenter study by the Japanese Red Cross Hospital Liver Study Group Toshie Mashiba Received Received
  FRI-159 Can HBcrAg and pre-genomic HBV RNA predict the risk of ALT flares after nucleoside analogue therapy withdrawal: delineating the clinical utility of new biomarkers? Ivana Carey Received Received
  SAT-159 Genetic determinants in critical domains of NS5A are associated with genotype 1b HCV-induced hepatocellular carcinoma Mohammad Alkhatib Received Received
  SAT-160 Timing of exposure to dimethyloxalylglycine-mediated hypoxia determines opposite effects in an experimental model of hepatitis C virus infection Matteo Nazzareno Barbaglia Received Received
  FRI-160 The role of soluble propragmmed cell death protein 1 on HBV relapse after cessation of entecavir therapy in HBeAg-negative non-cirrhotic patients Chien-Hung Chen Received Received
  THU-160 Outcomes of the national strategy on hepatitis C treatment with direct acting antivirals in a real-life setting: Results from a national survey in Slovenia Jerneja Videcnik Zorman Received Received
  SAT-161 Prevalence of HBV and syphilis co-infection in Ulaanbaatar population, Mongolia Delgerbat Boldbaatar Received Received
  THU-161 Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C treated with DAAs: Results from the German hepatitis C registry (DHC-R) Yvonne Serfert Received Received
  THU-162 The combination of sofosbuvir and daclatasvir is well tolerated and extremely effective in treating patients with hepatitis C with severe renal impairment including hemodialysis patinets Shahin Merat Received Received
  SAT-162 Serum HBV RNA as a predictor of incomplete HBV DNA suppression following initiation of nucleoside therapy in HBV/HIV co-infected individuals Ruth Byrne Received Received
  FRI-162 Prime-boost vaccination strategies using chimpanzee-adeno and MVA viral vectored vaccines encoding multiple HBV antigens (CPmutS) and class II invariant chain molecular adjuvants induces robust T-cell and anti-HBs antibody response in mice Senthil Kumar Chinnakannan Received Received
  SAT-163 HBeAg-negative chronic infection: more complex and conserved quasispecies in Hepatitis B X gene Maria Francesca Cortese Received Received
  THU-163 Efficacy and safety of direct-acting antivirals for hepatitis C in elderly patients: a systematic review and meta-analysis Marcus Maximilian Mcke Received Received
  FRI-163 Reduced liver-related complications after 13 years of follow-up of interferon-alpha treatment for HBeAg-positive chronic hepatitis B: The ELITE-B study Hannah Choi Received Received
  THU-164 High cure rates of hepatitis C in a genotype 3 predominant Pakistani community using generic direct acting antivirals Ammara Naveed Received Received
  SAT-164 Characterization of HBV kinetics during infection and treatment in primary human hepatocytes Harel Dahari Received Received
  FRI-164 Prognostic value of various liver scoring systems in cirrhotic chronic hepatitis B patients with and without tenofovir disoproxil fumarate treatment Jonggi Choi Received Received
  FRI-165 No detectable resistance to tenofovir in patients with Adefovir- and Entecavir-resistant chronic hepatitis B after 240 weeks of treatment with tenofovir disoproxil fumarate monotherapy Jonggi Choi Received Received
  THU-165 The risk of HBV reactivation among HBV/HCV co-infected patients treated with direct-acting antiviral agents: A single center experience Young Joo Park Received Received
  FRI-166 Treatment recommendations for chronic hepatitis B and the risk of hepatocellular carcinoma Moon Seok Choi Received Received
  THU-166 Treatment of 320 genotype 3 cirrhotic patients with 12 weeks of sofosbuvir/velpatasvir with or without ribavirin: Real life experience from Italy Luisa Pasulo Received Received
  SAT-166 Hepatitis C virus-based experimental models in the study of liver-driven altered glucose homeostasis Diana Gomes Received Received
  THU-167 Prevalence, linkage to care and treatment of hepatitis C virus in person who inject drugs under opioid substitution therapy in a Spanish area Ylenia Perez Castaño Received Received
  SAT-167 Hepatitis-E-genome sequencing via capture-probe targeting and NGS allows characterisation of viral variability Swantje Gundlach Received Received
  FRI-167 Effectiveness and safety with tenofovir alafenamide (TAF) for hepatitis B in US clinical practice NICOLE WICK Received Received
  FRI-168 Understanding HDV and HBsAg kinetics during nucleic acid polymer REP 2139 mono-therapy in HBeAg-negative chronic HBV/HDV co-infected patients via mathematical modeling Harel Dahari Received Received
  THU-168 Real-life effectivness and safety of glecaprevir/pibrentasvir in HCV infected patients with chronic kidney disease Andrea Aglitti Received Received
  THU-169 Genotype 4 RAS patterns in a European hepatitis C cohort Stephanie Popping Received Received
  FRI-170 Real-world effectiveness and renal safety of tenofovir alafenamide fumarate among chronic hepatitis B patients in Canada Mina Farag Received Received
  THU-170 Real-world effectiveness of elbasvir/grazoprevir in patients with hepatitis C virus genotype 4 infection: Results from a Veterans Affairs population Amy Puenpatom Received Received
  SAT-170 A phenotypic resistance assay for clinical HCV isolates could help rationalise DAA therapy in individuals experiencing recurrent virologic failure Christopher Jones Received Received
  THU-171 Effectiveness of elbasvir/grazoprevir in patients with hepatitis C virus genotype 1 infection receiving dialysis Amy Puenpatom Received Received
  SAT-171 HEV seroprevalence in blood donors in Turkey: Comparison of two commercial anti-HEV total Ab ELISA kit Senem Ceren Karatayli Received Received
  FRI-171 A phase 1 single ascending dose study of the safety, tolerability and pharmacokinetics of CRV431 Jill Greytok Received Received
  SAT-172 Novel mathematical modeling of HBsAg kinetics during long-term antiviral treatment: A pilot study Hwi Young Kim Received Received
  THU-172 Its the ribavarin, stupid: an analysis of 10,000 hepatitis C treatment monitoring encounters and the factors associated with side-effects and non-adherence ADELAIDE MARIA RANDAZZO Received Received
  FRI-172 Outcomes of response guided therapy with pegylated interferon alpha 2a in chronic hepatitis B and D George Sebastian Gherlan Received Received
  FRI-173 Modeling HBV kinetics in mice treated by a novel TLR7 agonist, alone or in combination with entecavir Antonio Gonalves Received Received
  THU-173 Sofosbuvir based anti-HCV therapy: Safe in hemodialysis Adnan Salim Received Received
  SAT-173 Global patterns of HBV genotype E epidemic dispersal from Africa determined using a full-genome phylogenetic and phylogeographic approach Evangelia-Georgia Kostaki Received Received
  THU-174 Efficacy of L-Carnitine on the ribavirin induced hemolytic anemia for patients with HCV infection Shinya Sato Received Received
  FRI-174 Discovery of novel therapeutic targets for decreasing HBsAg, focusing on host proteins binding to HBV RNAs Ryota Haba Received Received
  SAT-174 Formation of the occult chronic hepatitis B during antiviral therapy in patients with HIVHBVHDVHCV infection: Clinical cases Vitalii Sukachev Received Received
  THU-175 Eligibility and feasibility of hepatitis C treatment in the era of direct-acting antiviral agents: Our experience in real-world practice Monica Schiavini Received Received
  SAT-175 Recruitment of HBx on HBV DNA depends on FXR and is inhibited by FXR agonist Benot Lacombe Received Received
  FRI-175 Frequency,severity and impact of Peg-IFNa-associated flares in HDV infection: Results from the HIDIT-II study Svenja Hardtke Received Received
  THU-176 Weight gain after interferon-free clearance of chronic hepatitis C: Results from the German hepatitis C registry (DHC-R) Yvonne Serfert Received Received
  FRI-176 Orally administered TQ-A3334 to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics single and multiple ascending doses in healthy Chinese subjects Yue Hu Received Received
  SAT-176 The effect of HBV and HCV infection on pregnancy status Tadeusz, Wojciech Lapinski Received Received
  SAT-177 Loss of HBsAg by patients with high levels of HBV-DNA during treatment with nucleoside or nucleotide analogues Tadeusz, Wojciech Lapinski Received Received
  FRI-177 Association of prophylactic anti-HBV therapy with improved long-term survival in patients with hepatocellular carcionoma undergoing transarterial therapy Jeong Won Jang Received Received
  THU-177 Interim results of an ongoing project to eliminate chronic hepatitis C in people who inject drugs with ongoing intravenous drug use and a high risk of non-adherence to direct-acting antivirals in Vienna Caroline Schmidbauer Received Received
  THU-178 Drug-drug interactions in HCV therapy: Still relevant for clinical practice? Benjamin Schulte Received Received
  FRI-178 The clinical significance and predictors for precipitous HBsAg decline in off entecavir therapy HBeAg negative patients Rachel Wen-Juei Jeng Received Received
  THU-179 Never too old to be direct acting antiviral treated for hepatitis C virus David Mackie Received Received
  SAT-179 Human liver organoids culture as a novel in vitro model of HBV infection Chuan Kok Lim Received Received
  FRI-179 Antiviral therapy might not be required for chronic hepatitis B patients in the immune-tolerant phase with a significantly low incidence rate of liver-related events Mi Young Jeon Received Received
  SAT-180 Hepatitis delta genotype 1 and 3 do not replicate after coinfection in the same cell in vivo Marc Ltgehetmann Received Received
  FRI-180 JNJ-64530440, a novel capsid assembly modulator: single- and multiple-ascending dose safety, tolerability and pharmacokinetics in healthy volunteers Gail Edwards Received Received
  THU-180 Treatment of genotype 3 HCV infection in the large real-life Navigatore Lombardia multicentre cohort: Results from three different regimens Alessandro Soria Received Received
  THU-181 Safety and efficacy of glecaprevir/pibrentasvir for the treatment of HCV genotype 1-6: Results of the HCV-TARGET study eva hortas Received Received
  FRI-181 Efficacy and safety of switching therapy from tenofovir disoproxil fumarate to tenofovir alafenamide for hepatitis B virus infection Shun Kaneko Received Received
  SAT-181 Efficacy and safety of glecaprevir/pibrentasvir in patients with severe renal impairment in Japan: A prospective, multicenter study (KTK 49 Liver Study Group) Masanori Atsukawa Received Received
  SAT-182 Full length deep sequencing of South African hepatitis B virus isolates reveals increased viral diversity and X-gene deletions in hepatocellular carcinoma patients Anna McNaughton Received Received
  THU-182 The PRIORITIZE study: A pragmatic, randomized study of oral regimens for hepatitis C- transforming decision-making for patients, providers, and stakeholders eva hortas Received Received
  FRI-182 Anti-viral treatment in patients with immune tolerant-phase chronic hepatitis B may be cost-effective Hye-Lin Kim Received Received
  SAT-183 High resolution insight into hepatitis B virus infection and immunity in Africa to inform on intervention strategies Anna Mcnaughton Received Received
  THU-183 Prospective multicenter study of glecaprevir plus pibrentasvir combination therapy for patients with chronic hepatitis C Akihiro Tamori Received Received
  SAT-184 Approximation of the genotype distribution within global chronic hepatitis B virus infections Thomas Michler Received Received
  FRI-184 Function and drug combination studies in cell culture models for AB-729, a subcutaneously administered siRNA investigational agent for chronic hepatitis B infection Amy Lee Received Received
  THU-184 Correlates of unsuccessful hepatitis C virus therapy and recurrent viremia among active drug users: A mixed methods analysis Astou Thiam Received Received
  SAT-185 Is the performance of ultra-sensitive HBsAg Fujirebio assay consistent across HBV genotypes (comparison between CLEIA HBsAg HQ Fujirebio and Abbott Architect assays) Christiana Moigboi Received Received
  THU-185 Effectiveness and safety of DAA-based treatment of hepatitis C patients with severe and end stage chronic kidney diseases - EpiTer-2 database analysis Krzysztof Tomasiewicz Received Received
  FRI-185 Virological and immunological predictors of long-term ouctomes of peginterferon alfa-2a therapy for HBeAg-negative chronic hepatitis B I-Cheng Lee Received Received
  SAT-186 Pathophysiological impact of HCV on mitochondrial composition and functions Léa Monnier Received Received
  THU-186 Progress towards achieving hepatitis C elimination in the country of Georgia, April 2015-August 2018 Tengiz Tsertsvadze Received Received
  FRI-186 Entecavir plus pegylated interferon alfa-2a and sequential HBV vaccination increases the chance of HBsAg-seroclearance: Results from a randomized controlled EVIP trial Jeong-Hoon Lee Received Received
  SAT-187 characterization of hepatitis e infection in israel: identification of HEV-7 in camels and high seroprevalence in specific human populations Orna Mor Received Received
  FRI-187 Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and liver-related events in patients with chronic hepatitis B: A propensity score analysis Sung Won Lee Received Received
  THU-187 Objective evidence of neurocognitive impairment associated with hepatitis C virus infection and of its regression after viral clearance with direct antivirals Gloria Vaghi Received Received
  SAT-188 Expansion and genetic modification of primary hepatocytes to study long-term hepatitis B virus infection Paul Park Received Received
  FRI-188 Sequence analysis of baseline and on-treatment samples from HBV-infected chronic hepatitis B patients treated for 28 days with JNJ-56136379 monotherapy Gail Edwards Received Received
  THU-188 Retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C virus infection and prior DAA failure: An analysis from the German hepatitis C registry (DHC-R) Yvonne Serfert Received Received
  FRI-189 HBcrAg decline in JNJ-56136379-treated chronic hepatitis B patients: Results of a phase 1 study Gail Edwards Received Received
  SAT-189 GCAC1809-1812TTCT a novel viral quadruple mutation is strongly associated with basal core promotor double mutation and viral load in Hepatitis B e antigen negative chronic hepatitis B virus infected patients Kai-Henrik Peiffer Received Received
  THU-189 Role of comorbidites in sofosbuvir-based treatment response: Clinical experience from an Italian real life cohort Giulia Verzon Received Received
  SAT-190 Specific genetic elements in HBsAg C-terminus profoundly affect HBsAg levels in vivo, hamper HBsAg secretion in vitro and alter HBsAg structural stability in HBeAg-negative chronic HBV genotype D infection Lorenzo Piermatteo Received Received
  THU-190 Characteristics associated with sustained virologic response in chronic hepatitis C patients who received an abbreviated course of direct-acting antiviral therapy Kirsten Vest Received Received
  FRI-190 Incidence and predictors of flares after discontinuing nucleos(t)ide analogue therapy in HBeAg negative patients with chronic hepatitis B: Results from the randomized controlled STOP study Seng Liem Received Received
  SAT-191 Host genome integration of hepatitis B is prolific and is the primary contributor to viral HBs antigen gene expression Ondrej Podlaha Received Received
  THU-191 The cost-effectiveness of an HCV outreach intervention for at-risk populations in London, UK Zoe Ward Received Received
  FRI-191 EDP-514, a novel HBV core inhibitor with potent antiviral activity both in vitro and in vivo Kai Lin Received Received
  SAT-192 Targeting the HBx-DDB1-Cullin complex inhibits transcription from HBV covalently closed circular DNA in susceptible hepatoma cells Bingqian Qu Received Received
  THU-192 All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100 svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china Lai Wei Received Received
  FRI-192 Tenofovir disoproxil fumarate treatment in chronic hepatitis B patients with cirrhosis reduces hepatic decompensation, hepatocellular carcinoma and death Ken Liu Received Received
  FRI-193 Long-term renal and bone safety of tenofovir disoproxil fumarate in chronic hepatitis B patients with cirrhosis Ken Liu Received Received
  THU-193 4 week treatment for hepatitis C: A randomized controlled trial (4RIBC) Lone Wulff Madsen Received Received
  SAT-193 Evolutionary relationship among hepatitis B virus genotype D in Latin America and Europe João Renato Rebello Pinho Received Received
  SAT-194 The utility of monomeric HBV genomes for interrogating the HBV cccDNA minichromosome, using in vitro and in vivo models of HBV replication Peter Revill Received Received
  FRI-194 The novel antiviral agent inarigivir inhibits both nucleos(t)ide analogue and capsid assembly inhibitor resistant HBV in vitro Stephen Locarnini Received Received
  THU-194 Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5 or 6 infection: An integrated analysis of phase 2 and 3 studies Salil Sharma Received Received
  FRI-195 Long-term effect of nucleos(t)ide analogs on hepatitis B surface antigen in chronic hepatitis B patients Kenichi Morikawa Received Received
  SAT-195 The novel HBx mutation F30V correlates with HCC in vivo, hampers HBV replicative efficiency and enhances anti-apoptotic activity of HBx N-terminus in vitro Romina Salpini Received Received
  THU-195 An open-label, randomized, active control trial of 8 versus 12 weeks of elbasvir/grazoprevir for naive chronic hepatitis C genotype 1b patients with mild fibrosis (EGALITE): Impact of baseline viral loads and NS5A resitance-associated substitution Ming-Lung Yu Received Received
  THU-196 Efficacy of 8 versus 12-weeks treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8-weeks regimen in real world setting Dorota Zarebska-Michaluk Received Received
  FRI-196 The development of HCC in chronic hepatitis B patients with nucleos(t)ide analogs: Focus on hepatitis B surface antigen and core-related antigen Itaru Ozeki Received Received
  SAT-196 The integrated use of highly sensitive HBV markers can predict HBV reactivation in HBsAg-negative/Anti-HBc positive patients from oncohematological setting Romina Salpini Received Received
  SAT-197 Quality of life measurement using wrist actigraphy in HCV genotype 1 infected, treatment nave patients suffering from fatigue and receiving ombitasvir, paritaprevir, and ritonavir tablets and dasabuvir tablets (Viekirax/Exviera; 3D regimen) David Semela Received Received
  THU-197 Comparative effectiveness of 8 versus 12 weeks of ombitasvir/paritaprevir/ritonavir and dasabuvir in treatment-naive patients infected with HCV genotype 1b with non-advanced hepatic fibrosis Dorota Zarebska-Michaluk Received Received
  FRI-197 Prediction of elastographic reversion of cirrhosis after 5 years of entecavir or tenofovir disoproxil fumarate therapy in caucasian chronic hepatitis B patients George Papatheodoridis Received Received
  SAT-198 Full-length 5RACE analysis discriminates all major intracellular and extracellular viral RNAs during the course of infection Bernd Stadelmayer Received Received
  FRI-198 A Phase 1, double-blind, randomized, placebo-controlled, first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of oral JNJ-64794964, a toll-like receptor-7 agonist, in healthy adults Gail Edwards Received Received
  THU-198 Efficacy and safety of glecaprevir/pibrentasvir treatment for 8 weeks in treatment-naive patients with chronic hepatitis C virus infection without cirrhosis or with compensated cirrhosis: Analysis of data pooled from phase 2 and 3 studies Hannah Welz Received Received
  FRI-199 First in Human, single ascending dose clinical trial of AIC649 in patients with chronic hepatitis Daniela Paulsen Received Received
  THU-199 Awake the dormants: Barriers to access to care and cure in patients with chronic HCV infection Eli Zuckerman Received Received
  THU-200 The Real-Eorld Israeli experience of treating mild and severe chronic hepatitis C patients with elbasvir/grazoprevir: A large multi-center cohort study Eli Zuckerman Received Received
  FRI-200 Spend less get more;cost effectiveness of various models of care in hepatitis C treatment JEYAMANI RAMACHANDRAN Received Received
  FRI-201 Hepatitis B virus vaccine immunogenicity in anti-HBC immunocompromised patients with low anti-HBS levels: Preliminary results of the Hepbare study Mar Riveiro-Barciela Received Received
  SAT-201 Alternation of lipid metabolism and dysfunction of mitochondria might contribute to HCC development in the absence of overt necroinflammation Jaw-Ching Wu Received Received
  FRI-202 Outcomes of hepatitis B patients transplanted without hepatitis B immunoglobulin Sheetal Shah Received Received
  SAT-202 Endogenous and exogenous IFN responses suppress HDV persistence during proliferation of hepatocytes in vitro Zhenfeng Zhang Received Received
  THU-203 Hepatitis D infection and risk of hepatocellular carcinoma: A systematic review and meta-analysis of observational studies Dulce Alfaiate Received Received
  FRI-203 Inhibition of hepatitis B virus replication by FAM176A via activation of PI3K-AKT-mTOR signaling pathway Jie Yu Received Received
  SAT-204 Hepatitis E virus antigen in urine as a useful diagnostic method for monitoring infection and detection of recent infection Patrick Behrendt Received Received
  THU-204 Analysis of interleukin 28B rs12979860 polymorphism relationship with spontaneous clearance of hepatitis D virus infection in Mongolian population Zaya Batsuuri Received Received
  FRI-204 ASPP2: A potential strategy to inhibit HBV replication through reducing hepatocytes autophagy Ying Shi Received Received
  THU-205 Evaluation of HBV outcomes after treatment discontinuation from 4 phase 3 studies eva hortas Received Received
  FRI-205 Entecavir improves liver function and fibrosis in hepatitis B virus-associated cirrhosis: A 6 years-multicenter study Seung Kak Shin Received Received
  SAT-205 Associated risk factors for hepatitis E seroprevalence among liver transplant recipients Petra Dinjar Kujundi&263; Received Received
  SAT-206 The impact of hepatitis E virus infection on the Scottish solid organ transplant population Mhairi Donnelly Received Received
  FRI-206 Relationship between hepatitis B core related antigen levels and sustained HBeAg seroconversion in patients treated with nucleos(t)ide analogues Milan Sonneveld Received Received
  THU-206 HBV DNA relapse after stopping nucleoside analogue therapy in patients with HBsAg loss: Detectable pre-genomic HBV RNA is a better predictor of relapse than ultra-sensitive HBsAg - implications for HBV cure Ivana Carey Received Received
  FRI-207 Subgroup analysis of patients undergoing switch of nucleos(t)ide regimen for HBV treatment during the prospective BONIKA trial Kathrin Sprinzl Received Received
  THU-207 A retrospective review of the incidence of hepatocellular carcinoma in patients with chronic hepatitis B attending the regional hepatitis clinic in Northern Ireland Geraldine Carroll Received Received
  SAT-208 Zinc/Ribavirin: A possible treatment option in chronically HEV genotype 3 infected patients without SVR under ribavirin monotherapy Thomas Horvatits Received Received
  FRI-208 Predictors of treatment response during addition of pegylated Interferon alfa-2a to an onging nucleos(t)id treatment in chronic hepatitis B: Results from the PADD-ON trial Martin Sprinzl Received Received
  THU-208 Characterization of a novel chemiluminescent enzyme immunoassay for the quantitation of antibodies to hepatitis B core antigen class IgG and correlation with intrahepatic HBV covalently-closed-circular DNA Gian Paolo Caviglia Received Received
  SAT-209 Role of estrogen and its receptors in HEV associated feto-maternal outcomes Premashis Kar Received Received
  FRI-209 Exploring TH1/TH2 adjuvants to improve the efficacy of the therapeutic vaccination against chronic hepatitis B Jinpeng Su Received Received
  THU-209 Dynamics of a transient elastography-based risk prediction model for hepatocellular carcinoma treated with antiviral therapy in chronic hepatitis B: A multi-center retrospective cohort study from the Korean Transient Elastography Study Group Hye Yeon Chon Received Received
  SAT-210 Circulation of hepatitis a genotypes in Israel 2017-2018: Environmental surveillance supports clinical findings Orna Mor Received Received
  FRI-210 Establishment of high rates of functional cure of HBeAg negative chronic HBV infection with REP 2139-Mg based combination therapy: Ongoing follow-up results from the REP 401 study Andrew Vaillant Received Received
  FRI-211 Evaluation of the safety and tolerability of transaminase flares during antiviral therapy in patients with HBeAg negative chronic HBV infection or HBV/HDV co-infection Andrew Vaillant Received Received
  SAT-211 HEV infection in Italy: Beyond the hepatic disease Giovanna Picchi Received Received
  THU-211 Evaluation of point shearwave elastography using acoustic radiation force impulse imaging for non-invasive assessment of liver fibrosis in HBeAg-negative chronic HBV infection: A prospective longitudinal study Christiana Graf Received Received
  FRI-212 HBV RNA can be detected more frequently than HBcrAg but decreases during long term treatment with nucleos(t)ide analogues up to 14 years in patients with HBeAg negative chronic hepatitis B eva hortas Received Received
  SAT-212 Treatment with mTOR inhibitors is an independent risk factor for chronic hepatitis E in transplant patients with increased transaminases levels Mar Riveiro-Barciela Received Received
  THU-212 Reactivation of occult HBV infection in HIV treated for HCV: A retrospective study Bianca Granozzi Received Received
  SAT-213 Hepatitis E virus prevalence in Flemish blood donors Ann-Sofie Vercouter Received Received
  FRI-213 HBV RNA at 6 months predicts HBeAg loss in nucleos(t)ide analogue treated HBeAg positive patients: Demonstration of clinical utility? Bo Wang Received Received
  THU-213 Distinct features of hepatitis delta in a Mediterranean setting Helena Hernàndez-Èvole Received Received
  SAT-214 Incidence, predictors and prognosis of liver failure in patients with hepatitis E as an acute insult Yijin Wang Received Received
  THU-214 Annual average of integral FIB-4 index and HBV core-related antigen as an appropriate indicators for starting nucleoside analogues at an optimum timing Shuhei Hige Received Received
  FRI-214 Novel hepatitis B virus X gene mutants emerge during antiviral therapy to increase covalently closed circular DNA accumulation conferring pseudo-drug-resistance and increaing hepatocellular carcinoma risk Chau-Ting Yeh Received Received
  FRI-215 Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: 144 weeks results of phase 3 trial Hyung Joon Yim Received Received
  SAT-215 Cryoglobulinemia in asymptomatic, symptomatic acute and chronical HEV infections Thomas Horvatits Received Received
  THU-215 Association between core mutations and annual decline rate of HBVDNA and HBsAg in chronic hepatitis B patients treated with nucleoside analogue Takashi Honda Received Received
  THU-216 Rapid turnover of HBV cccDNA in nucleoside-treated chronic hepatitis B patients during drug resistance emergence and breakthrough Qi Huang Received Received
  FRI-217 Safety, antiviral activity, and pharmacokinetics of a novel hepatitis B virus capsid assembly modulator, JNJ-56136379, in Asian and non-Asian patients with chronic hepatitis B Gail Edwards Received Received
  THU-217 Low risk of HBV reactivation in a large European cohort of HBV/HCV coinfected patients treated with DAA Jerzy Jaroszewicz Received Received
  SAT-217 Effectiveness and safety of sofosbuvir-based regimens in treatment of chronic HCV patients aged 60 years and older, egyptian single center experience Shereen Abdel Alem Received Received
  SAT-218 Impact of sofosbuvir-based therapy on renal functions indices in chronic hepatitis c patients who achieved sustained virological response Reham Abdelmoniem Received Received
  FRI-218 Dynamic changes of serum hbv pgrna levels in patients with chronic hepatitis B treated with entecavir or peg-interferon XIAOQI YU Received Received
  SAT-219 Effect of treatment of hepatitis C by directly acting antivirals on chronic hepatitis C and B co-infected patients Ayman Sadek Received Received
  THU-219 Long-term outcome in Caucasian patients with hepatitis B e antigen-negative chronic infection: An observational cohort study zgr Koc Received Received
  FRI-219 RO7049389, a core protein allosteric modulator, demonstrates robust decline in HBV DNA and HBV RNA in chronic HBV infected patients mingfen zhu Received Received
  SAT-220 Higher frequency of occult HCV infection in HIV/HCV coinfected patients with advanced liver disease: Post DAAs treatment observation Sabrina Bagaglio Received Received
  SAT-221 Autoantibodies to apolipoprotein A1 (apoA-1): A new prognostic biomarker in HCV infection Margaret Bassendine Received Received
  THU-222 The application of novel HBV pgRNA assay to predict HBeAg clearance on long-term nucleos(t)ide analogues Daryl Lau Received Received
  FRI-222 Redundancy of elastography in mono-infected HCV individuals less than 30 years old - Development of Dillons Rule Paul Brennan Received Received
  SAT-222 Improvement in liver fibrosis among patients with hepatitis C who achieved sustained viral response after direct acting antivirals treatment, in country of Georgia George Kamkamidze Received Received
  FRI-223 Contribution of HBV and HCV infection in mortality of B-NHL subjects Myagmarjav Budeebazar Received Received
  SAT-223 AA genotype of the deSNP rs6726639 of gene MERTK (MER Tyrosine Kinase) is associated with development of hepatocellular carcinoma after hepatitis C virus clearance Vincenza Calvaruso Received Received
  SAT-224 Design and validation of a risk prediction model for hepatocellular carcinoma development after sustained virological response in chronic hepatitis C patients Ho Soo Chun Received Received
  FRI-224 Reaching out to the undiagnosed people with hepatitis C infection in Belgium: A pilot study Dana Busschots Received Received
  THU-225 Risk prediction model for hepatocellular carcinoma after hepatitis b e antigen seroclearance in patients treated with entecavir or tenofovir Tae Seop Lim Received Received
  FRI-225 Universal access to direct-acting antivirals treatment is not not enough to prevent late stage presentation of hepatitis C infection Joaquin Cabezas Received Received
  SAT-225 The risk of hepatic decompensation is reduced, but not abolished after direct-acting antivirals: The role of portal hypertension Elton Dajti Received Received
  FRI-226 Modeling early viral kinetics during observed HCV acute infection in post lung transplantation recipients Harel Dahari Received Received
  THU-226 Concomitant diabetes mellitus increases risk of liver fibrosis in treatment-naive chronic hepatitis B with low viral loads: Results from a matched case-control study Hei Chun Justin Ma Received Received
  SAT-226 beneficial effects of DAAs on right cardiac function in hcv patients with low-mild liver fibrosis Andrea Dalbeni Received Received
  SAT-227 Clinical but not genetic variables predict the development of hepatocellular carcinoma in hepatitis C cirrhotic patients treated with direct-acting antivirals: A 3-year study in 509 patients Elisabetta Degasperi Received Received
  FRI-227 Interleukin-6 -174G/C genotype and interleukin-10 ATA haplotype are associated with clinical comorbidities in chronic hepatitis C patients Luciana Diniz Silva Received Received
  THU-227 NTCP S267F variant associates with decreased susceptibility to HBV infection and decelerated progression of related liver diseases Thanh Binh Mai Received Received
  THU-228 HBV RNA can influence HBV viral load results depending on the test used Ed G. Marins Received Received
  SAT-228 Sustained virologic response induced by direct-acting antivirals suppresses skeletal muscle loss in patients with type C liver disease Kei Endo Received Received
  FRI-228 Community-based hepatitis C treatment of people who inject drugs and their injecting network is feasible and effective: Results from the TAP (Treatment And Prevention) study Joseph Doyle Received Received
  SAT-229 Risk of hepatocellular carcinoma in patients with chronic hepatitis C and stage-3 liver fibrosis after sustained virological response with direct acting antivirals Maria Sanchez-Azofra Received Received
  FRI-229 Reflex testing in patients with chronic hepatitis C in Spain improves healthcare outcomes and is cost effective Federico Garcia Garcia Received Received
  THU-229 Increased gaps in hepatitis B pregnancy care identified among low-risk populations Rena Mei Received Received
  THU-230 HBV and HDV confection trends in HIV patients in Vienna Caroline Schmidbauer Received Received
  SAT-230 HCV re-infection among HIV-infected MSM in New York City Daniel Fierer Received Received
  SAT-231 Impact of the HCV cure with DAAs in the use of concomitant medication and the serum lipid profile: Follow-up data one year after the SVR12 Elena González-Colominas Received Received
  FRI-231 Hostel-based models can improve the engagement of homeless individuals with liver services: VALID (vulnerable adults liver disease) study Ahmed Hashim Received Received
  THU-231 Risk of hepatocellular carcinoma in patients with immune-tolerant chronic hepatitis B Gyeol Seong Received Received
  FRI-232 An outpatient endoscopy-based patient navigator model improves hepatitis C virus screening among high risk patients: A 3-year prospective observational study among a safety-net health system Grishma Hirode Received Received
  THU-232 Hepatitis B vaccination is effective among HIV-infected adults in Uganda Emmanuel Seremba Received Received
  SAT-232 Reinfection following successful HCV DAA therapy among people with recent injecting drug use Jason Grebely Received Received
  SAT-233 Hepatitis C virus reinfection following antiviral treatment among people who inject drugs: A systematic review, meta-analysis, and meta-regression Behzad Hajarizadeh Received Received
  FRI-233 The impact of community-based rapid point-of-care testing on enhancing uptake of hepatitis C treatment for people who inject drugs in needle and syringe services Jessica Howell Received Received
  FRI-234 Viral interference between dengue virus and hepatitis C virus infections Jee-Fu Huang Received Received
  SAT-234 Risk of hepatocellular carcinoma and efficacy of direct-acting antivirals in patients with concurrent hepatitis C virus Elizabeth Harrod Received Received
  THU-234 High body-mass index is associated with increased risk of alanine aminotransferase elevation and hepatocellular carcinoma in chronic hepatitis B patients with sustained viral control Chengcong Chen Received Received
  SAT-235 Low HCV reinfection incidence following DAA treatment scale-up in people living with HIV in Australia Samira Hosseini Hooshyar Received Received
  THU-235 Hepatitis B virus testing and cascade of care in a tertiary referral centre, Maastricht The Netherlands Eva Van Oorschot Received Received
  FRI-235 Hepatitis C virus risk factors and test uptake in an English prison Kathryn Jack Received Received
  THU-236 Integration of HBV DNA near cancer-related genes in HBsAg-negative hepatocellular carcinoma patients Danny Wong Received Received
  FRI-236 Hepatitis C virus related liver fibrosis in people who inject drugs at the Stockholm Needle Exchange evaluated with liver elasticy Martin Kberg Received Received
  SAT-236 Post-treatment fibrotic modifications overwhelm pretreatment liver fibrosis in predicting HCC in CHC patients with curative antivirals Chung-Feng Huang Received Received
  THU-237 Increasing prevalence of indications to choose bone/renal-friendly antiviral drug: A territory-wide study of 135,414 patients from 2000 to 2017 Grace Wong Received Received
  FRI-237 Triple E (engagement, education and eradication) for patients chronically infected with hepatitis C: Results of a self-sustaining, comprehensive education, screening and treatment program for patients in substance abuse treatment facilities Jane Ranagan Received Received
  SAT-237 Histological improvement of hepatitis C virus patients after achieving sustained virological response with direct-acting antivirals Rui Huang Received Received
  SAT-238 The impact of SVR from direct acting antiviral and interferon- based treatments for HCV on hepatocellular carcinoma risk in a large population based cohort Naveed Janjua Received Received
  THU-238 Low rates of antiviral therapy among treatment-eligible adults with chronic hepatitis B virus infection Robert Wong Received Received
  THU-239 Improving patient knowledge about hepatitis B virus leads to improvements in HBV disease monitoring Robert Wong Received Received
  SAT-239 Real life data on elbasvir/grazoprevir efficacy, safety and drug-drug interaction profile in patients with chronic hepatitis C viral infection: A prospective analysis in the PITER cohort Loreta Kondili Received Received
  FRI-239 SAMBA II HCV: A new point of care molecular assay for HCV diagnostics and DAA monitoring Sonny Michael Assennato Received Received
  FRI-240 Comparison of Abbott RealTime HCV genotype II, Abbott HCV genotype plus RUO with Roche Cobas HCV genotyping assays for hepatitis C virus genotyping Chen-Hua Liu Received Received
  SAT-240 Metabolic liver function improves 12 weeks after successful sofosbuvir-based direct-acting antiviral therapy in patients with chronic hepatitis C and advanced liver disease Tea Lund Laursen Received Received
  SAT-241 The dynamics of two plasma markers of type III collagen formation and degradation in the course of chronic hepatitis C viral clearance with direct-acting antiviral therapy Tea Lund Laursen Received Received
  FRI-241 Barriers to HCV elimination among drug users: HepCare-Spain Juan Macías Received Received
  THU-241 Influence of HBV genotype on the risk of hepatocellular carcinoma: mediating roles of different phase of viral infection and epigenetic modifications Wan-Jung Wu Received Received
  FRI-242 Absence of hepatitis C infection despite high-risk sexual behavior in a cohort of men who have sex with men screened in the community: preliminary results of SEXCHECK study Pietro Malosso Received Received
  THU-242 Clinical non-invasive markers for hepatic inflammation and fibrosis assessment in chronic hepatitis B with normal alanine aminotransferase Zhao Wu Received Received
  SAT-242 Liver stiffness measurement is not a predictive factor of HCC in HCV patients with severe fibrosis who achieved SVR by DAA Aline Le Cleach Received Received
  THU-243 Occult hepatitis B virus infection after haploidentical haematopoietic stem cell transplantation patients: incidence and characterization of HBV pres/s gene mutations haiying zhang Received Received
  FRI-243 Utility of simple serum based tests to exclude cirrhosis prior to HCV treatment in non-hospital based settings Jonathan Mitchell Received Received
  SAT-243 Ledipasvir/sofosbuvir is highly effective and safe in patients with chronic hepatitis B virus and hepatitis C virus coinfection: Final study results eva hortas Received Received
  FRI-244 Platelet-derived growth factor alpha might mediate hepatic fibrosis by enhancing insulin resistance in patients with hepatitis C Anna Mrzljak Received Received
  THU-244 Virological and clinical characteristics of chronic hepatitis delta patients of Mongolia Delgersaikhan Zulkhuu Received Received
  SAT-244 Mixed cryoglobulinemia patients with persisting symptoms after SVR are characterized by B-cell clonality markers Serena Lorini Received Received
  FRI-245 Improvement in cognitive impairment following 12 weeks of aerobic exercise in individuals with non-cirrhotic, chronic hepatitis C Philip OGorman Received Received
  SAT-245 Prospective evaluation of the impact of hepatitis C cure on sexual dysfunction Zoe Mariño Received Received
  SAT-246 Overall survival and incidence of liver-related events in a cohort of cirrhotic patients treated with direct antiviral agents: Results from a multicenter study Chiara Masetti Received Received
  FRI-246 Elimination of HCV in a Large Urban Health System in the United States: A Big-data Approach Ponni Perumalswami Received Received
  FRI-247 Influence of HCV coinfection and HCV treatment on risk of diabetes mellitus in HIV infected persons Lars Peters Received Received
  SAT-247 The evaluation of the inhibitory effect of oral anti-hepatitis C virus agents on carcinogenesis Seiichi Mawatari Received Received
  FRI-248 Cost-effectiveness of elbasvir/grazoprevir (EBR/GZR) for treatment-naive (TN) patients with chronic hepatitis C virus (HCV) genotype 1b (GT1b) infection in Russia Shelby Corman Received Received
  SAT-248 Patients treated for HCV and listed for LT in a French multicenter study: What happens at 3 years ? Lucy Meunier Received Received
  SAT-249 Increased cardiovascular risk associated with chronic hepatitis C infection still remains at SVR24 Ann Monaghan Received Received
  FRI-249 HCV in french prisoner, the study 2017: Fewer patients but more treatment than in 2015 André-Jean Remy Received Received
  FRI-250 Test to cure: Increase outreach linkage to care by use of real time HCV viral load André-Jean Remy Received Received
  SAT-250 Effects of sustained virological response on the endothelial dysfunction and the cardiovascular risk in hepatitis C after direct antiviral angets treatment: HEPCAR study Rocío Muñoz-Hernández Received Received
  SAT-251 The association of serum IFN-?3 levels with liver fibrosis and hepatocarcinogenesis in chronic hepatitis C patients treated with direct-acting antiviral agents Miyako Murakawa Received Received
  THU-251 Metabolic risk factors for advanced liver disease among alcohol risk users in the general population Fredrik berg Received Received
  FRI-251 Impact of hepatitis C treatment on patterns of drug use and subsequent treatment outcomes: High SVR rates despite increasing intravenous drug use in the post treatment period Trina Ritchie Received Received
  FRI-252 Comparing the efficacy of hepatitis C diagnostic pathways: Standard testing vs. targeted testing Emma Robinson Received Received
  THU-252 Nursing staff volume is the most significant predictor of improved in-hospital mortality among alcoholic hepatitis patients admitted with ascites or hepatic encephalopathy: US nationwide population-based study Hassan Azhari Received Received
  SAT-252 Long-term effect of direct-acting antivirals therapy in patients with hepatitis C-related decompensated cirrhosis: Russian single academic center experience Ekaterina Nabatchikova Received Received
  SAT-253 Impact of HCV clearance on HCC development and patient survival: Propensity score-matched analysis of an ongoing database of 2173 CHC patients Mina Nakagawa Received Received
  THU-253 Equal efficacy of gastric and jejunal tube feeding in liver cirrhosis and/or alcoholic hepatitis: A randomised controlled trial Palle Bager Received Received
  FRI-253 Changing epidemiology of hepatitis C: A Hospital-level study Joana Roseira Received Received
  SAT-254 Incidence of hepatocellular carcinoma and mortality after HCV elimination by all-oral DAA therapy: Results from a large-scale, multicenter cohort study Eiichi Ogawa Received Received
  THU-254 Cumulative effects of WESTERN DIET and ALCOHOL abuse: A novel MODEL of ASH/NASH-derived liver injury Raquel Benedé Received Received
  FRI-254 The impact of virally induced hepatic inflammation and low to moderate alcohol consumption on liver transient elastography (Fibroscan) in patients with chronic hepatitis C virus infection treated with direct-acting antivirals Christoffer Ruus Received Received
  FRI-255 Dynamics of HCV epidemiology among HIV patients in Vienna Caroline Schmidbauer Received Received
  SAT-255 Long-term safety and efficacy results in hepatitis C virus genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir dasabuvir /- ribavirin in the TOPAZ-I and TOPAZ-II trials Salil Sharma Received Received
  THU-255 Long term outcomes of alcoholic patients without clinical evidence of liver disease: A 15 years follow-up study Sonia Bernardo Received Received
  SAT-256 Influence of metabolic syndrome on fibrosis regression regulated by LOXL-2 after SVR ANGELA PUENTE Received Received
  THU-256 Alpha-1 antitrypsin ameliorates experimental alcoholic liver disease and predicts patient outcome Grander Christoph Received Received
  FRI-256 Procoagulant imbalance in chronic hepatitis C and its relationship with cardiovascular and liver damage Giordano Sigon Received Received
  SAT-257 Incidence and predictors of liver outcomes in chronic hepatitis C patients: Comparison of an American and a Chinese cohort Huiying Rao Received Received
  THU-257 Fungal dysbiosis in alcoholic patients is associated with the severity of the liver injury eva hortas Received Received
  FRI-257 Making OraQuick quicker: A hepatitis C point-of-care assay reduced to five minutes for viremic individuals David Smookler Received Received
  SAT-258 Indocyanine green retention test predicts the risk of portal hypertension-related events after direct-acting antiviral therapy in compensated advanced chronic liver disease patients Federico Ravaioli Received Received
  FRI-258 Sustained virologic response among non-cirrhotic persons who inject drugs: Results from the CanHepC retrospective hepatitis C registry Alyssa Margeson Received Received
  THU-258 Comparison of a fast corticosteroid tapering with the standard corticosteroid schedule in severe alcoholic hepatitis Berta Cuyas Received Received
  FRI-259 Characteristics and sustained virologic response of persons reporting illicit substance use in the past 6 months: Results from the CANUHC prospective patient registry Alyssa Margeson Received Received
  SAT-259 Achieving accelerated elimination of hepatitis C virus infection by 2025: A case study in France Yuri Sanchez Received Received
  THU-259 The gene signature-MELD score and alcohol consumption determine long-term prognosis of patients with severe alcoholic hepatitis Pierre Deltenre Received Received
  THU-260 Alcoholic cirrhosis is associated with higher in-patient mortality compared to non-alcoholic cirrhosis Xiaowen Fan Received Received
  SAT-260 Global timing of hepatitis C virus elimination: estimating the year countries will achieve the World Health Organization elimination targets Yuri Sanchez Gonzalez Received Received
  FRI-260 Improving hepatitis C care cascade through electronic health engagement Zohha Tariq Alam Received Received
  SAT-261 Elevated HCV reinfection rates after cure on spontaneous clearance among HIV-infected and uninfected men who have sex with men Carmine Rossi Received Received
  FRI-261 Large-scale screening is not useful to identify individuals with hepatitis B or C virus infection: Final results of a Swiss prospective study Aicha Djebali-Trabelsi Received Received
  THU-261 Validation of the pre-treatment neutrophil-to-lymphocyte ratio to predict response to corticosteroids in severe alcoholic hepatitis Ewan Forrest Received Received
  THU-262 A modified Glasgow alcoholic hepatitis score incorporating the neutrophil-to-lymphocyte ratio is superior to other baseline scores of prognosis in alcoholic hepatitis Ewan Forrest Received Received
  SAT-262 Long-term liver function outcome and related risk factors in HCV cirrhotic patients treated with direct-acting antiviral therapy: Results from the Navigatore platform in Veneto-Italy Francesco Paolo Russo Received Received
  FRI-262 Genetic variants in the promotor region of the macrophage migration inhibitory factor are associated with severity of HCV-induced liver fibrosis Theresa Wirtz Received Received
  FRI-263 The VirAEmiC project: Opt out hepatitis B and C testing of 38704 patients in an urban emergency department Terence Wong Received Received
  THU-263 The demonstration of antibodies to histone 2B of the IgA-type helps to differentiate between alcoholic liver disease and non-alcoholic fatty liver disorder Amelie Frank Received Received
  SAT-263 Immediate versus delayed hepatitis C treatment is cost-saving in the United Kingdom: A pan-genotypic cost-effectiveness analysis Yuri Sanchez Gonzalez Received Received
  FRI-264 Silencing clusterin supress the progression of hepatitis C virus-related HCC by regulating autophagy and attenuating HCC cell properties Xiaoxiao Zhang Received Received
  SAT-264 Prediction of hepatocellular carcinoma development using liver stiffness after sustained virological responses by magnetic resonance elastography in patients with chronic hepatitis C Nobuharu Tamaki Received Received
  SAT-265 Anti-VHC therapy does not increase de risk of developing splanchnic vein thrombosis in patients with cirrhosis Fanny Turon Received Received
  FRI-265 Twelve weeks of effective resistance training did not change the gut microbiota in patients with cirrhosis Luise Aamann Received Received
  THU-265 In severe alcoholic hepatitis, serum transferrin indicates impaired HNF4a signaling and predicts mortality independently of disease severity Karim Hamesch Received Received
  SAT-266 High rates of early HCV reinfections after DAA therapy in active intravenous drug users attended at mobile harm reduction units Jorge Valencia Received Received
  SAT-267 Occult hepatitis C in immunocompetent patients who have achieved sustained viral response is associated with persistent histological abnormality Yijin Wang Received Received
  FRI-267 Serial measurement of serum dextran absorption by novel competition ELISA demonstrates larazotide acetate significantly improves leaky gut in a Western diet murine model of metabolic liver disease Rebecca Caffrey Received Received
  THU-267 the increasing burden of alcohol related liver disease: A single tertiary centre experience Arif Hussenbux Received Received
  SAT-268 Noninvasive prediction of gastroesophageal varies by serum wisteria floribunda agglutinin positive Mac-2 binding protein and FIB-4 index in chronic hepatitis C Keiya Watakabe Received Received
  THU-268 Human microfibrillar-associated protein 4 expressed in the liver and serum in alcoholic liver disease predicts liver fibrosis severity with accuracy similar to transient elastography and enhanced liver fibrosis test Ditlev Rasmussen Received Received
  FRI-268 Microbiota signature differs significantly between NAFLD and healthy controls but not between NAFL and NASH Mnevver Demir Received Received
  FRI-269 Regulation of lymphangiogenesis by Paneth cells in normal physiology and experimental portal hypertension MOHSIN HASSAN Received Received
  THU-269 Abnormal lipoproteins in alcoholic hepatitis cause hepatocellular injury via inflammasome activation Maria Perez-Matos Received Received
  SAT-269 The sustained deleterious impact of viremia on patient reported outcomes in patients with chronic hepatitis C who dont achieve sustained virologic response Zobair Younossi Received Received
  FRI-270 Association between gut microbiota and hepatocellular carcinoma in patients with chronic liver disease Takashi Honda Received Received
  THU-270 Severe alcoholic hepatitis has no influence on prognosis of variceal bleeding in patients with alcoholic cirrhosis Fischer Petra Received Received
  THU-271 Metabolic syndrome increases the risk of hepatic fibrosis in subjects with increased alcohol consumption: Results from a population-based cohort ELISA POSE Received Received
  SAT-271 Genetic risk factors for advanced alcoholic and non-alcoholic liver disease in the general population Fredrik berg Received Received
  FRI-271 Rifaximin alleviates endotoxemia with improved intestinal hyperpermeability with partially modified fecal microbiota in cirrhotic patients Kosuke Kaji Received Received
  SAT-272 A simple algorithm based on electronic medical records to identify NAFLD with advanced fibrosis in patients with Type 2 diabetes Naim Alkhouri Received Received
  FRI-272 Identification of novel glycans that target gut microbiota-associated ammonia production Amy Doherty Received Received
  THU-272 A study investigating the effect of extracorporeal cellular therapy with C3A cells on the survival of alcoholic hepatitis designed along the guidelines of the NIAAA Jan Stange Received Received
  THU-273 Role of PNPLA3 rs738409 and MBOAT7 rs626283 during alcohol detoxification: Indication of different mechanisms for fibrosis development Vanessa Rausch Received Received
  FRI-273 Intestinal microbiota signature related to hbeag seroconversion after oral antiviral therapy Jin-Shui Pan Received Received
  FRI-274 Exercise modulates gut microbiota and intestinal barrier functionality counteracting early obesity and NAFLD in an in vivo model David Porras Received Received
  SAT-274 Repeatability and reproducibility of multiparametric magnetic resonance imaging of the liver in children Daniel Halliday Received Received
  THU-275 Blood transcript modules differentiate steroid responders from non-responders at baseline in severe alcoholic hepatitis Shvetank Sharma Received Received
  SAT-275 Interleukin-32 as a novel NAFLD biomarker in PNPLA3 I148M variant carriers Guido Alessandro Baselli Received Received
  FRI-275 Fecal microbiota profiles as a diagnosis marker in PSC and PSC-IBD patients compare to healthy controls Michal Safran Received Received
  SAT-276 Point shear wave elastography by ElastPQ accurately stages hepatic fibrosis in patients with NAFLD: A prospective, multicentric study David Bauer Received Received
  THU-276 Women, Native Americans, and Asians experience the greatest increase in alcoholic hepatitis hospitalizations: An analysis of the 2008-2014 U.S. nationwide inpatient sample Farah Shirazi Received Received
  FRI-276 Effect of korean red ginseng on non-alcohlic steatohepatitis: Randomized controlled trial Ki Tae Suk Received Received
  THU-277 Significant differences in alcoholic hepatitis related mortality in the United States by sex, race/ethnicity, and insurance: An analysis of the 2008-2014 nationwide inpatient sample Farah Shirazi Received Received
  SAT-277 Screening diabetic patients at risk for complications of non-alcoholic fatty liver disease: Prospective evaluation of national and international guideline recommendations Valentin Blank Received Received
  FRI-277 Effect of probiotics in the treatment of NASH: A randomized clinical trial Gabriela Zanatta Port Received Received
  FRI-278 RIP3-dependent signalling exerts divergent effects on liver steatosis and carcinogenesis in experimental non-alcholic fatty liver disease Marta B. Afonso Received Received
  SAT-278 Integrated analysis of dna methylation and mRNA expression to identify mechanisms of non-alcoholic steatohepatitis Noemí Cabré Received Received
  SAT-279 Comparison of different and new types of non-invasive fibrosis tests in NAFLD Paul Cales Received Received
  FRI-279 Stat2 is a pathogenic factor in human non-alcoholic steatohepatitis and mouse models of liver injury and mediates fatty acid-induced Inflammasome activation in hepatocytes Wenhao Li Received Received
  FRI-280 Common dietary component, wheat amylase trypsin inhibitors, driver of chronic liver disease in pre-clinical models of NASH and liver fibrosis Muhammad Khan Received Received
  SAT-280 Comparison of CAP, MRI-PDFF, Steatotest, FLI and HSI performances for diagnosing NAFLD and NASH in morbidly obese patients undergoing bariatric surgery Laurent Castera Received Received
  THU-280 Quantitative fibrosis assessment independently predicts outcome in alcoholic liver disease Rudolf Stauber Received Received
  SAT-281 Protease activity sensors for non-invasive monitoring of NASH Sophie Cazanave Received Received
  FRI-281 IL-4 receptor alpha knock-out mice are protected against fibrotic NASH in a representative mouse model of non-alcoholic steatohepatitis Muhammad Khan Received Received
  THU-281 Single nucleotide polymorphisms associated with no interferon lambda 4 production are associated with reduced mortality in alcoholic hepatitis Sidsel Sty Received Received
  THU-282 Augument of liver regeneration protects against ethanol-induced acute liver injury by promoting autophagy YUAN Wu Received Received
  SAT-282 Decrease in HbA1c accounts for the rapid decline in the measurement of liver stiffness by transient elastography in diabetic patients Tugba Celebi Received Received
  FRI-283 Impact on NAFLD of long-term weight loss after bariatric surgery Chiara Barbieri Received Received
  SAT-283 Plasma acylcarnitines are biomarkers of magnetic resonance imaging-proton density fat fraction response in NASH patients treated with the ACC inhibitor GS-0976 Michael Charlton Received Received
  THU-283 FGF15 deficiency aggregates experimental alcoholic steatohepatitis in mice: A critical role for lipocalin 2 signaling Min You Received Received
  THU-284 Hepatocyte-specific deletion of splicing factor SRSF3 exacerbates experimental alcoholic steatohepatitis in mice Min You Received Received
  FRI-284 A combination of fenofibrate with a liver-targeted acetyl-CoA carboxylase inhibitor enhances efficacy while reversing plasma triglyceride increases in a murine model of NASH Eva Hortas Received Received
  SAT-284 Diagnostic performance of transient elastography on liver fibrosis of patients with non-alcoholic fat hepatitis Chun-Yan Wang Received Received
  SAT-285 Fibroscan-based score for detection of active nash and significant fibrosis is better than fib-4 in 361 chronic hepatitis B patients with non-alcoholic fatty liver disease Xiaoling Chi Received Received
  THU-285 Loss of X-Box Protein-1 in intestinal epithelial cells promotes the development of alcoholic liver disease in the liver Kang ZHENG Received Received
  FRI-285 The benchmarks obeticholic acid and elafibranor show variable effects on NASH and hepatic fibrosis in diet-induced or chemically-induced animal models FRANCOIS BRIAND Received Received
  SAT-286 Application of guidelines for fatty liver in two prospective cohorts of human immunodeficiency virus positive patients Sila Cocciolillo Received Received
  SAT-287 A novel non-invasive index based on extracellular matrix markers can identify NAFLD patients with active disease and significant fibrosis: analysis of the CENTAUR study Samuel Daniels Received Received
  FRI-288 Physiological levels of cardiotrophin-1 (CT-1) contribute to fasting-induced free fatty acid mobilization David Carneros Trujillo Received Received
  SAT-288 Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease Victor de Ledinghen Received Received
  FRI-289 Effect of MSDC-0602K treatment on the metabolome of a diet-induced murine model Jerry Colca Received Received
  SAT-289 Follow-up of NAFLD/NASH progression using an automated histological image analysis Maxime De Rudder Received Received
  SAT-290 Association of liver inflammation and fibrosis score with non-invasive biomarkers in non-alcoholic fatty liver disease: Preliminary results from the MAST4HEALTH study Konstantinos Apostolou-Karampelis Received Received
  FRI-290 The role of bile acids profile and insulin reistance for the prediction of gallstone disease in a prospective cohort of blood donors Elton Dajti Received Received
  FRI-291 Glucokinase sensitizes hepatocarcinoma cells to the lipogenic activity of fructose and controls accumulation of lipid droplets and secretion of triglyceride-rich lipoproteins Olivier Diaz Received Received
  SAT-291 Identifying NAFLD at the source: A novel approach to capturing nonalcoholic fatty liver disease in a diabetes practice Amreen Dinani Received Received
  THU-291 Is non-alcoholic fatty liver disease a risk factor for chronic kidney disease? Takemi Akahane Received Received
  THU-292 The natural history of NASH-induced advanced fibrosis in a large cohort of patients with type-2 diabetes Naim Alkhouri Received Received
  SAT-292 Effectively reducing screen failure rate in non-alcoholic fatty liver disease clinical trial using the FibroScan-based FAST score combining liver stiffness, controlled attenuation parameter and AST Céline Fournier Received Received
  SAT-293 Combination of FibroScan and FibroMeter (FibroMeter VCTE) improves identification of patients with advanced fibrosis in patients with NAFLD Céline Fournier Received Received
  FRI-293 Recipient PNPLA3 and TM6SF2 genotypes and risk of NAFLD folllowing liver transplantation Speranta Iacob Received Received
  THU-293 Increased risk of advanced liver disease independently of classic metabolic risk factors or drug induced hepatotoxicity in patients with psoriasis María Teresa Arias Loste Received Received
  THU-294 Non-invasive measures of liver fibrosis in NAFLD is associated with cardiovascular risk Sebastian Bachmayer Received Received
  SAT-294 Automated quantitation of steatosis, inflammation, ballooning and fibrosis using machine learning in routine histological images of liver biopsies of patients with NAFLD Roberta Forlano Received Received
  FRI-294 Mitochondrial GNMT-complex II is recovered by miR-873-5p targeting in NAFLD David Fernández Ramos Received Received
  FRI-295 Advanced glycation end products (AGEs) exacerbate NAFLD progression to liver fibrosis via receptor for AGEs (RAGE) in high fat fed mice Hettya Kandage Dinali Helan Fernando Received Received
  THU-295 Nonalcoholic fatty liver disease is associated with QTc lengthening in the general population Bubu Banini Received Received
  SAT-295 Diagnostic accuracy of non-invasive methods (NFS Score and FIB-4) for detecting advanced fibrosis: A validation study of NFS score and FIB-4 in a cohort of South Indian patients with NAFLD Joe Francis Received Received
  FRI-296 Interaction between the soluble guanylate cyclase and the NLRP3 inflammasome in Kupffer cells: Implications for the anti-inflammatory actions of sGC stimulation in liver Roger Flores-Costa Received Received
  SAT-296 Oxidized LDL is a distinctive biomarker of NASH independently of liver fibrosis in patients with NAFLD Rocío Gallego-Durán Received Received
  THU-297 Prediction of NAFLD progression according to duration of exposure to obesity and diabetes: New approach to adapt therapeutic and research strategies Pierre Bauvin Received Received
  FRI-297 Trans-signaling blockade induces mature-onset obesity and insulin resistance in mice via suppression of PPARalpha Eithan Galun Prof. Received Received
  SAT-297 Prediction of incident severe liver disease in the general population using non-invasive scoring systems Hannes Hagstrm Received Received
  THU-298 Clinical characteristics of NAFLD/NASH patients from gastroenterology and endocrinology clinics Rachel Botchlett Received Received
  FRI-298 Hypoxia-inducible factor 2 alpha drives lipid accumulation in human hepatocytes through the fatty acid translocase CD36 Carmelo García-Monzón Received Received
  SAT-298 MR elastography based fibrosis correlates with clinical liver events in patients with non-alcoholic fatty liver disease: A multi-center study Ma Ai Thanda Han Received Received
  SAT-299 Assessment of NIS4 clinical utility for identification of patients with active NASH (NAS=4) and significant fibrosis (F=2) in patients at risk of NASH Axelle Louard Received Received
  FRI-299 Transcriptomic and epigenetic characterization of a NAFLD murine model Antonio Gil-Gómez Received Received
  FRI-300 E2F2 mediated repression of fatty acid B-oxidation is mitigated through CREB1 in progressive non-alcoholic fatty liver disease Francisco Gonzalez-Romero Received Received
  SAT-300 Prospective liver biopsy-based prevalence of non-alcoholic fatty liver disease and steatohepatitis among a large middle-aged population utilizing FibroScan, LiverMultiscan and magnetic resonance elastography to guide liver biopsy Céline Fournier Received Received
  THU-300 Prevalence of NAFLD in patients with a first episode of stroke and impact on the mortality and severity at 3 months Teresa Broquetas Received Received
  SAT-301 The FibroScan-based FAST score combining liver stiffness, controlled attenuation parameter and AST can efficiently screen for presence of at risk fibrotic NASH: Evaluation in an American cohort of patients screened for NAFLD Céline Fournier Received Received
  THU-302 Association between advanced fibrosis in fatty liver disease and overall mortality in terms of body size and body fat distribution Goh Eun Chung Received Received
  SAT-302 Predicting the severity of hepatic steatosis and fibrosis by transient elastography and MRI-based techniques in adults patients with suspected NAFLD Céline Fournier Received Received
  FRI-302 Impact of exercise on advanced fibrotic stage of NASH and liver carcinogenesis Maria Guarino Received Received
  SAT-303 Liver fibrosis together with PNPLA3 p.I148M variant affects quality of life in patients with non-alcoholic fatty liver disease: prospective liver stiffness-based study Lena Heintz Received Received
  THU-303 Report from the trenches: Real-life challenges to recruitment and enrollment in NAFLD clinical trials Amreen Dinani Received Received
  SAT-304 The association between visceral fat and evolution of patients with nonalcoholic fatty liver disease Marta Hernández Conde Received Received
  THU-304 Modeling NAFLD-related disease progression among the PITER SVR12 cohort Chris Estes Received Received
  FRI-304 Elafibranor and pioglitazone reduce NASH and fibrosis in a genetically-obese dietary-induced NASH mouse model Katie Headland Received Received
  FRI-305 Long acting GLP-1/Glucagon co-agonist ameliorates steatosis, inflammation and fibrogenesis in a rodent model of NASH Dorte Holst Received Received
  SAT-305 Alignment between physician-estimated versus objectively derived fibrosis scores in non-alcoholic steatohepatitis: Real-world evidence suggests clinicians underestimate disease severity in secondary care Nathan Williams Received Received
  THU-305 Comparing perceptions of illness among patients with chronic liver disease Izza Sattar Received Received
  FRI-306 RIP3 deficiency restores mitochondrial bioenergetics and function in experimental NAFLD Tawhidul Islam Received Received
  THU-306 Liver function tests in NAFLD: Changes in upper normal limits, does it really matter? Roberta Forlano Received Received
  SAT-306 Autotaxin is a valuable biomarker for predicting liver fibrosis in patients with non-alcoholic fatty liver disease Yasushi Honda Received Received
  THU-307 Whipple procedure increases the risk for non-alcoholic fatty liver disease Jordan Goldstein Received Received
  FRI-307 Metadoxine prevents diet-induced non-alcoholic steatohepatitis in mice Du Jinghua Received Received
  SAT-307 A direct comparative study among magnetic resonance elastography, vibration controlled transient elastography and shear wave elastography in patients with nonalcoholic fatty liver disease Kento Imajo Received Received
  FRI-308 Inhibition of alpha 2A adrenergic receptors reduces liver inflammation in experimental NASH Helen Jones Received Received
  THU-308 More than 4 times higher healthcare costs for end-stage liver disease patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis Nandita Kachru Received Received
  SAT-308 The optimal cut-off points of FIB-4 index for predicting the incidences of HCC and extra-hepatic malignancies in biopsy-proven Japanese NAFLD patients Takanori Ito Received Received
  THU-309 Cardiovascular risk assessment and management improves outcomes in a specialist multidisciplinary non-alcoholic fatty liver disease clinic Atul Goyale Received Received
  FRI-309 Hepatitis B virus B and T cell specific responses are reduced in adults with a body mass index 35 and non-alcoholic fatty liver disease and in a mice model of NAFLD compared to adults with a BMI of 35 patients and normal animals Shivali Joshi Received Received
  SAT-309 Prevalence of NAFLD and metabolic syndrome in rural and regional Victoria, Australia William Kemp Received Received
  THU-310 Non-alcoholic steatohepatitis is associated with a higher risk of advanced colorectal neoplasm Jimin Han Received Received
  SAT-310 Real-world evaluation of NASH in US clinical practice: Underutilization of liver biopsy and liver imaging NICOLE WICK Received Received
  FRI-310 Alcohol dehydrogenase activity in liver and blood is altered in non-alcoholic fatty liver disease Finn Jung Received Received
  FRI-311 Gut lymphatic vascular disorder associates with severity of cirrhosis in non-alcoholic fatty liver disease Savneet Kaur Received Received
  THU-311 Liver enzymes cut offs in patients with advanced non-alcoholic fatty liver disease: A multi-center study Ma Ai Thanda Han Received Received
  SAT-311 The PDGFR-beta containing PRTA-score is a novel non-invasive diagnostic algorithm for significant liver fibrosis in patients with viral, alcoholic, and metabolic liver disease Joeri Lambrecht Received Received
  THU-312 Physician-recommended lifestyle interventions and associated effects among non-alcoholic steatohepatitis patients with and without cardiovascular-metabolic related comorbidities: A European real-world study Nathan Williams Received Received
  FRI-312 Increased levels of bile acid in feces plays an important role in pathophysiology of nonalcoholic steatohepatitis eva hortas Received Received
  THU-313 Differences between non-alcoholic steatohepatitis patient characterisation and management approaches: A multinational real-world study Nathan Williams Received Received
  FRI-313 A novel farnesoid X receptor agonist, TERN-101, reduces liver steatosis, inflammation, ballooning and fibrosis in a murine model of non-alcoholic steatohepatitis Kevin Klucher Received Received
  SAT-313 Exosomal miRNA analysis for classifying severity of disease in biopsy-proven NAFLD patients Young-Sun Lee Received Received
  FRI-314 A novel semicarbazide-sensitive amine oxidase inhibitor, TERN-201, reduces NAS and fibrosis in rodent models of non-alcoholic steatohepatitis Kevin Klucher Received Received
  SAT-314 Liver fibrosis by FibroScan is highly prevalent in type 2 diabetic patients with NAFLD and fairly normal liver enzymes but increased uric acid Rosa Lombardi Received Received
  THU-314 Serum Zinc levels as a prognostic factor for extra-hepatic carcinogenesis in Japanese patients with non-alcoholic liver disease Takanori Ito Received Received
  FRI-315 Lipoprotein lipase deficiency in myeloid cells aggravates the progression of non-alcoholic steatohepatitis Anja Koop Received Received
  THU-315 Non-cirrhotic patients with non-alcoholic fatty liver disease have impaired quality of life: Independently predicted by body mass index, diabetes and liver stiffness Benjamin Kadler Received Received
  FRI-316 Liver fetuin-A in activated macrophages is a key feature of non-alcoholic steatohepatitis in mice and humans Nicolas Lanthier Received Received
  THU-316 Cognitive impairment or hepatic encephalopathy? A prospective cross-sectional study in patients with non-alcoholic fatty liver disease Helena Katchman Received Received
  SAT-317 Fibroscan as a tool to improve cardiovascular disease stratification: Truth or myth? Rui Magalhaes Received Received
  THU-317 The prescribing patterns and use of statins in patients with non-alcoholic fatty liver disease Stephanie Watkins Received Received
  THU-318 Elevated urinary bisphenol A levels are associated with nonalcoholic fatty liver disease among adults in the United States Donghee Kim Received Received
  FRI-318 Effects of fatty acids and polyphenols from extra virgin olive oil in a murine animal dietary model knockout for the LDL receptor Álvarez Amor Leticia Received Received
  SAT-318 Comparative accuracy of NAFLD fibrosis score, apri score, and FIB-4 score in predicting significant fibrosis in African Americans and Caucasians with non-alcoholic fatty liver disease Hemnishil Marella Received Received
  FRI-319 HEME oxygenase-1 mediates mitochondrial dysfunction in non-alcoholic steatohepatitis Dongdong Li Received Received
  SAT-319 Fibroblast growth factor 21 is independently associated with severe hepatic steatosis in non-obese HIV-infected patients Michael Praktiknjo Received Received
  THU-319 Association between body size-metabolic phenotype and nonalcoholic steatohepatitis and significant fibrosis Saekyung Joo Received Received
  SAT-320 The use of the fatty liver index and fibroscan to determine the prevalence of non-alcoholic fatty liver disease in an Irish population Louise Rabbitt Received Received
  THU-320 Evaluation of atherosclerosis and coronary artery stenosis of non-alcoholic fatty liver disease Yoshihito Kubotsu Received Received
  FRI-320 TM6SF2 silencing impairs lipid metabolism and trafficking in HepG2 cells carrying the I148M PNPLA3 variant and MBOAT7 deletion Miriam Longo Received Received
  FRI-321 Hepatocyte expression of the protein kinase ERK5 regulates insulin sensitivity Giulia Lori Received Received
  THU-321 Fluorodeoxyglucose perfusion and uptake in abdominal organs is associated with hepatic disease state in patients with non-alcoholic fatty liver disease Alexander Kuo Received Received
  SAT-321 Liver fibrosis scores predict mortality in the general population Cristina Ripoll Received Received
  SAT-322 Comparison of point shear wave elastography (ElastPQ-pSWE) and FibroScan Transient Elastography (F-TE) for liver fibrosis staging in patients with NAFLD Davide Roccarina Received Received
  THU-322 Statin use on development and progression of nonalcoholic fatty liver disease: A nationwide cohort study Jung Il Lee Received Received
  FRI-322 Metabolic inflammation: The role of chemokine C-C motif ligan 2 in the crosstalk between liver tissue and muscle Fedra Luciano Received Received
  SAT-323 Selenoprotein P levels discriminate the degree of hepatic steatosis and are related to the NAS score in patients with non-alcoholic fatty liver disease Chiara Rosso Received Received
  THU-323 Impact of genetic polymorphisms associated with NAFLD on hepatic and vascular complications in diabetes Rosa Lombardi Received Received
  FRI-323 Pegbelfermin (BMS-986036) reduces serum levels of secondary bile acids in patients with non-alcoholic steatohepatitis Candy Zhu Received Received
  FRI-324 Introducing a new pre-clinical model of advanced NASH that mimics the main pathophysiologic characteristics and transcriptomic signature of the human disease Jordi Gracia-Sancho Received Received
  THU-324 Non-alcoholic fatty liver disease causes dissociated changes in metabolic liver functions Peter Lykke Eriksen Received Received
  SAT-324 Sonic hedgehog immunohistochemistry is a tissue biomarker of ballooned hepatocytes Michael Schild Received Received
  SAT-325 Implementation of a primary care shear-wave elastography-based pathway to identify non-alcoholic fatty liver disease patients with advanced fibrosis in a large North American urban population Abdel-Aziz Shaheen Received Received
  THU-325 Regional liver function investigated by galactose positron emission tomography is reduced in patients with non-alcoholic steatohepatitis Peter Lykke Eriksen Received Received
  FRI-325 rs641738 CT variant near MBOAT7-TMC4 increases risk of fibrosis, NASH, and HCC: A meta-analysis Jake Mann Received Received
  THU-326 Relative fat mass: A new definition of obesity and NAFLD Mariana Machado Received Received
  SAT-326 Influence of NAFLD diagnosed by controlled attenuation parameterin patients of chronic hepatitis B with mildly elevated alt MUHAMMAD ASIM Received Received
  FRI-326 Preclinical evaluation of endothelial dysfunction by peripheral artery tonometry and its correlations with untargeted metabolomic profiles Mario Masarone Received Received
  THU-327 Lifestyle modification leads to a significant decline in aminotrasnsferase activity even without weight reduction in children with non-alcoholic fatty liver disease Anna Mania Received Received
  FRI-327 Liver mitochondrial hydrogen sulfide oxidation: From nutritional physiology to non-alcoholic fatty liver pathology Ins Mateus Received Received
  THU-328 The prevalence of NAFLD in morbidly obese subjects revisited Abraham Meijnikman Received Received
  SAT-328 Controlled attenuation parameter for evaluating liver steatosis in type 2 diabetes patients Ioan Sporea Received Received
  SAT-329 Ethyl glucuronide inhair uncovers a high rate of harmful alcohol consumption in patients with presumed NAFLD Katharina Staufer Received Received
  FRI-329 Comparison of seladelpar and combinations with liraglutide or selonsertib for improvement of fibrosis and NASH in a diet-induced and biopsy-confirmed mouse model of NASH eva hortas Received Received
  SAT-330 Whole metabolome profiling identifiesthe combination of an eicosanoid, a bile acid and an androgen as a highly accurate marker of liver fibrosis in patients with non-alcoholic fatty liver disease Felix Stickel Received Received
  THU-330 Biochemical liver tests reflect the genetic risk for fatty liver disease with increasing body weight but not with alcohol consumption Elena Mueller Received Received
  THU-331 Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non-alcoholic fatty liver disease: The importance of an elevated mean platelet volume Benjamin H. Mullish Received Received
  FRI-331 Do N1-methylnicotinamide and nicotinamaide administration defferentially alleviated hepatic steatosis? Makoto Nakamuta Received Received
  SAT-331 Use of machine learning to predict diagnosis codes for non-alcoholic steatohepatitis in administrative healthcare data Laura Telep Received Received
  THU-332 Healthcare resource utilisation, demographics, and comorbidities by diagnosis codes and histological stage in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis in a large integrated healthcare delivery system in the U.S Lisa Nyberg Received Received
  FRI-332 Effect of combined farnesoid X receptor agonist and angiotensin 2 receptor blocker on established liver fibrosis in rats Tadashi Namisaki Received Received
  THU-333 The HSD17B13:TA (rs72613567) splice variant protects against severity of non-alcoholic fatty liver disease but not fibrosis Rafael Paternostro Received Received
  SAT-333 Non-alcoholic steatohepatitis significantly decreases microsomal liver function in the absence of fibrosis, which allows the use of the 13C-aminopyrine breath test for its non-invasive detection Wim Verlinden Received Received
  FRI-333 ATG7 genetic variant and defective autophagy: A novel risk factor for non-alcoholic fatty liver disease progression in patients with type 2 diabetes mellitus Serena Pelusi Received Received
  FRI-334 Cerium oxide nanoparticles present antilipogenic and anti-inflammatory effects in rats with diet-induced non-alcoholic fatty liver disease Meritxell Perramon Corominas Received Received
  THU-334 PNPLA3 rs738409 CG variant predicts liver-related events and death in non-alcoholic fatty liver Salvatore Petta Received Received
  SAT-334 Liver steatosis in HIV-positive patients with and without HBV coinfection accessing care in a programmatic setting in Africa Giovanni Villa Received Received
  SAT-335 A simple biomarker panel predictive of advanced fibrosis in patients with non-alcoholic steatohepatitis Zobair Younossi Received Received
  THU-335 FXR rs35724 CG variant modulates cholesterol levels, carotid atherosclerosis and liver damage in non-alcoholic fatty liver Salvatore Petta Received Received
  FRI-336 Lack of CCL2 limits the development of HCC in a model of obesity-associated carcinogenesis Benedetta Piombanti Received Received
  SAT-336 lLver stiffness measurement: An alternative practical predictor for early kidney dysfunction in patients with non-alcoholic fatty liver disease Ming-Hua Zheng Received Received
  THU-336 Possible ways of concomitant hypothyroidism effect on the course of nonalcoholic fatty liver disease Vasyl Prysyazhnyuk Received Received
  THU-337 Cardiovascular risk factors and fibrosis severity in NAFLD: is there a link? Davide Roccarina Received Received
  SAT-337 Evaluation of anti-fibrotic properties of OCA and INT-767 in an in vitro system of NAFLD Beatrice Anfuso Received Received
  THU-338 Prevalence and dynamics of NAFLD-associated fibrosis among HIV from first presentation to last follow-up Caroline Schmidbauer Received Received
  FRI-338 Mitochondrial uncoupler HU6 reduces hepatic oxidative stress in the DIAMOND(TM) mouse model, thus abrogating NASH development Francisco Portell Received Received
  SAT-338 Oral arginine supplementation attenuates the progression of steatosis to non-alcoholic steatohepatitis through preventing translocation of bacterial endotoxin Anja Baumann Received Received
  SAT-339 Socioeconomic deprivation is associated with non-response to lifestyle interventions in non-alcoholic fatty liver disease Kris Bennett Received Received
  FRI-339 Clinical translatability of a diet-induced obese mouse model of non-alcoholic steatohepatitis Kristoffer Rigbolt Received Received
  THU-339 The relationship between the PNPLA3, TLL1 polymorphism combination and advanced fibrosis in Japanese patients with non-alcoholic fatty liver disease Yuya Seko Received Received
  FRI-340 In vivo effects of a novel inhibitor of apoptosis signal-regulating kinase 1 in mouse models of liver injury and metabolic disease Manuel Roqueta-Rivera Received Received
  THU-340 Epidemiology of NAFLD and advanced fibrosis in the French general population: A population-based cohort study in 118,664 subjects (NASH-CO study) Lawrence Serfaty Received Received
  FRI-341 Sexual aspects of liver metabolism: A computational approach Damjana Rozman Received Received
  SAT-341 MET409, an optimized sustained FXR agonist, was safe and well-tolerated in a 14-day phase 1 study in healthy subjects Hubert Chen Received Received
  THU-341 Liver steatosis is a strong predictor of mortality and cancer in chronic hepatitis B regardless of viral load Amir Shlomai Received Received
  SAT-342 Morphometric collagen analysis discerns anti-fibrotic effects of INT-767 and OCA in NASH mouse models using second harmonic generation imaging Li Chen Received Received
  FRI-342 Combining probiotics and an angiotensin-2 type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non-alcoholic steatohepatitis Yasuhiko Sawada Received Received
  THU-343 Systematic review: Patient reported quality of life outcomes in non-alcoholic fatty liver disease: Effect of disease severity and duration Humaira Ud-Din Received Received
  SAT-343 Alagebrium ameliorates NAFLD progression in mice fed a high advanced glycation end products diet via direct inhibition of Kupffer cells and indirect inhibition of hepatic stellate cell activation Hettya Kandage Dinali Helan Fernando Received Received
  FRI-343 NEDDylation inhibition as a new potential therapy of non-alcoholic fatty liver disease Marina Serrano-Macia Received Received
  FRI-344 Preclinical characterization of FM101, a first-in-class A3 adenosine receptor modulator for the treatment of non-alcoholic steatohepatitis Changho Shon Received Received
  SAT-344 MSDC-0602K targets the mitochondrial pyruvate carrier to treat non-alcoholic steatohepatitis BRIAN FINCK Received Received
  THU-344 The influence of non-alcoholic fatty liver disease on a two year prognosis of the patients with stable coronary heart disease depending on SYNTAX score II Iryna Vakalyuk Received Received
  SAT-345 Novel mitochondrial pyruvate carrier modulators to treat non-alcoholic steatohepatitis and insulin resistance Brian Finck Received Received
  THU-345 Lean NAFLD patients have lower prevalence of cardiovascular, metabolic and severe liver disease compared to overweight or obese patients with NAFLD Stephanie Watkins Received Received
  SAT-346 Icosabutate induces a potent reduction in hepatic oxidative stress in rodent models of metabolic stress and fibrosing NASH David Fraser Received Received
  FRI-346 The effect of exercise training and canagliflozin on hepatic lipid metabolism of nonalcoholic fatty liver disease Kenichi Tanaka Received Received
  THU-346 Plasma ApoE levels are associated with non-alcoholic fatty liver disease: the PREVEND cohort study Eline H. Wouters-Van Den Berg Received Received
  SAT-347 MRI-PDFF response in MGL-3196 and placebo treated patients predicts reduction in ballooning and inflammation components of NAS and NASH resolution in a 36-week serial liver biopsy study Stephen Harrison Received Received
  THU-347 Economic and clinical burden of non-alcoholic steatohepatitis in patients with type II diabetes in the United States Zobair Younossi Received Received
  THU-348 Patients with non-alcoholic steatohepatitis experience severe impairment of health related quality of life Zobair Younossi Received Received
  SAT-348 Low frequencies of lifestyle interventions and liver-specific medications in a multicentric prospective real world NAFLD cohort: The fatty liver assessment in Germany (FLAG) study Wolf Peter Hofmann Received Received
  SAT-349 Improvement of hepatic inflammation and fibrosis independently of weight loss from a short, individualized, web-based exercise program in patients with NAFLD Yvonne Huber Received Received
  FRI-349 Development of humanized nonalcoholic steatohepatitis model using chimeric mice with highly repopulated humanized livers Chise Tateno Received Received
  SAT-350 YH25724, a novel long-acting GLP-1/FGF21 dual agonist, exhibits marked anti-fibrotic effects in different experimental models of liver fibrosis Junhwan Kim Received Received
  FRI-351 DNA methylation pattern of TM6SF2 influences NAFLD progression in genotype-dependent manner Burge Ulukan Received Received
  SAT-351 Biomarkers and clinical characteristics associated with nonalcoholic steatohepatitis fibrosis progression in the CENTAUR study Nicolas Lanthier Received Received
  FRI-352 Inflammation provokes hepatic but not adipose tissue diacylglycerol acyltransferase 2 expression and concomitant triglyceride synthesis in an experimental non-alcoholic fatty liver disease Balasubramaniyan Vairappan Received Received
  SAT-353 The effect of metformin on hepatic fatty acid partitioning; an investigation using human in vivo and in vitro models Thomas Marjot Received Received
  FRI-354 Novel Gubra Amylin NASH diet-induced obese mouse model of biopsy-confirmed non-alcoholic steatohepatitis Sanne Veidal Received Received
  SAT-354 Aramchol, SCD1 inhibitor, improves liver glucose homeostasis in NASH Luba Litinetsky Received Received
  SAT-355 Fatty liver trends in Southern Italy: Mediterranean or Americanized lifestyle habits? Emilio Molina Molina Received Received
  FRI-355 Elafibranor, a drug candidate for first line NASH monotherapy and a universal backbone for drug combination treatment Axelle Louard Received Received
  FRI-356 Single cell peripheral innate and adaptive immune signature of non-alcoholic steatohepatitis by cytometry time of flight Kathryn Waller Received Received
  SAT-356 Anti-metabolic, anti-inflammatory and anti-fibrotic properties of ART-648, a novel phosphodiesterase 4 inhibitor as a potential clinical candidate for non-alcoholic steatohepatitis Hiroshi Nagabukuro Received Received
  SAT-357 Tropifexor, a farnesoid X receptor agonist for the treatment of nonalcoholic steatohepatitis: Interim results based on baseline body mass index from first two parts of Phase 2b study FLIGHT-FXR Arun Sanyal Received Received
  FRI-357 Fibrinogen-like protein 2 aggravates non-alcoholic steatohepatitis by enhancing inflammatory signaling in macrophages Xiaojing Wang Received Received
  SAT-358 Sodium glucose cotransporter 2 inhibitor, canagliflozin ameliorate liver function in Japanese patients with type 2 diabetes mellitus: Subgroup analyses of clinical trials Yuya Seko Received Received
  FRI-358 Differentiation of glucagon and glucagon-like peptide-1 effects on hepatocytes Xiaozhen Wang Received Received
  FRI-359 Ductular reaction predicts the progression of non-alcoholic fatty liver disease Ramy Younes Received Received
  SAT-359 Pharmacokinetics and safety of pegbelfermin (BMS-986036) administered in the abdomen and upper arm to normal, overweight, and obese healthy participants Candy Zhu Received Received
  FRI-360 The role of Paneth cells in the pathogenesis of non-alcoholic fatty liver disease: A potential gut microbiota-associated mechanism Saisai Zhang Received Received
  FRI-361 Impact of cardiovascular complications on patients outcome after orthotopic liver transplantation Niklas Aehling Received Received
  FRI-362 Exercise training for liver transplant candidates Bandar Aljudaibi Received Received
  THU-363 Lipid nanoparticle pre-treatment improves adeno-associated virus diffusion in the primate liver and enables an increase of therapeutic transgene expression Karin Kwikkers Received Received
  FRI-363 Iron metabolism imbalance is associated with increased mortality following orthotopic liver transplantation Edouard Bardou-Jacquet Received Received
  THU-364 Liver cT1 predicts clinical outcomes in patients with chronic liver disease Arjun Jayaswal Received Received
  FRI-364 Frequency and impact of discordance between pre-transplant imaging and explant histology on post liver transplant outcomes for patients with hepatocellular carcinoma Amine Benmassaoud Received Received
  FRI-365 Efficacy of combined partial hepatectomy and cyst fenestration on health-related quality of life in polycystic liver disease Lucas H.P. Bernts Received Received
  THU-365 Adeno-associated virus-serotype-specific transduction patterns in mice and non-human primates liver tissue: Implications for therapeutic efficacy Anna Majowicz Received Received
  FRI-366 Portal vein thrombosis in patients on the waiting list for liver transplantation: A single center cohort study Xavier Verhelst Received Received
  FRI-367 Pre-liver transplant profile of cardiovascular risk factors and its impact on early post-transplant outcome Claudia Chialà Received Received
  THU-367 Linking diabetic cardiovascular disease with non-alcoholic fatty liver disease through L-carnitine: A hyperpolarized MRS study Dragana Savic Received Received
  THU-368 Multimodal pre-clinical imaging of liver inflammation and fibrosis Anja Schmidt-Christensen Received Received
  THU-369 Efficacy and safety of endoscopic ultrasound-guided liver biopsies in parenchymal liver diseases: A systematic review and meta-analysis Anup Shah Received Received
  FRI-369 The role of adipose tissue in metabolic and cardiovascular complication after liver transplantation Daria DAmbrosio Received Received
  THU-370 Quantification of hepatic metal overload by laser ablation inductively coupled plasma mass spectrometry imaging (LA-ICP-MSI) Ralf Weiskirchen Received Received
  FRI-370 Application of an extended-release tacrolimus formulation allows dose reduction and stabilizes graft function after liver transplantation Alexandra Frey Received Received
  FRI-371 Correlation between classification of circulating tumor cells in peripheral blood and early recurrence in patients with hepatocellular carcinoma after liver transplantation Binsheng Fu Received Received
  THU-371 Modulation of H3K27 methylation by EZH2 and UTX/JMJD3 small molecules inhibitors impacts on proliferation and differentiation of hepatic progenitor cells and differentiated hepatocytes plasticity Laura Belloni Received Received
  SAT-371 Alleviation in NK cells cytotoxicity following inhibitions of Neuroligin-4 (NLG4) receptor by recombinant beta-neurexin involving IL-4 pathway Johnny Amer Received Received
  SAT-372 High prevalence of anti HLA Class II de novo donor-specific antibodies during rejection after liver transplantation Jordi Colmenero Received Received
  FRI-372 Next generation sequenzing outperforms standard microbiological cultivation for detection of bacteria in the biliary tract in patients with ischemic type biliary lesions and/or anastomotic stricture Bjrn Grobe Received Received
  THU-372 Exosomes from human umbilical cord mesenchymal stem cells promote liver regeneration in aged mice after major hepatectomy via activating sirtuin1 pathway Liang Chen Received Received
  FRI-373 Mismatch in C-locus Eplets between donor and recipient as independent factor of acute T-cell mediated rejection in liver transplantation Sandra Guiral Foz Received Received
  THU-373 IL-6 trans-sginaling controls liver regeneration after partial hepatectomy nastaran Fazel Modares Received Received
  SAT-373 Peritoneal mucosal-associated invariant T cells functionally differ from their exhausted circulating counterparts in decompensated cirrhosis Oluwatomi Ibidapo-Obe Received Received
  SAT-374 Interleukin 35 exerts its suppressive function in chronic liver failure through the induction of an immunosuppressive HLA-GCD4 regulatory T -cell population Wafa Khamri Received Received
  FRI-374 Von Willebrand factor independently predicts mortality on the waitlist for liver transplantation and facilitates additional risk stratification in low MELD patients Georg Gyoeri Received Received
  THU-374 The INCRNA H19-dervied MIR-675 promotes liver necroptosis by targeting fadd Maytal Gefen Received Received
  SAT-375 Therapeutic interleukin 4 modulates monocyte dynamics and accelerates repair and regeneration following acute liver injury Ruairi Lynch Received Received
  FRI-375 Direct oral anticoagulants are safe and effective in patients after liver/kidney transplantation Adam Herber Received Received
  THU-375 Transcription factor TRIM33 controls liver progenitor cell towards hepatocyte differentiation through synergizing with SMAD2/3 following massive parenchymal loss Tao Lin Received Received
  FRI-376 Early treatment with sorafenib and mTOR inhibitor in recurrent hepatocellular carcinoma after liver transplantation: Safety and survival Federica Invernizzi Received Received
  THU-376 A viral mediated liver repopulation assay without the use of transgenic animals Wei-Yu Lu Received Received
  SAT-376 Bile acids induce STAT3 and repress FOXP3 expression in hepatic CD4 lymphocytes under cholestatic conditions Alexander Miethke Received Received
  THU-377 Systemic blood pressure is not associated with hepatic perfusion and metabolic activity by 18F-FDG PET in patients with NAFLD Souvik Sarkar Received Received
  FRI-377 Survival outcome after liver transplantation in US patients with hepatocellular carcinoma Mohamed Saleh Ismail Received Received
  SAT-377 Significant reductions in intrahepatic Mucosal Associated Invariant T cells with increased terminal activation marker expression amongst NAFLD patients following a 12 week aerobic exercise program: a paired liver biopsy study Sara Naimimohasses Received Received
  SAT-378 The NIF mouse as a model for acute, late stage non-alcoholic steatohepatitis Julia Nilsson Received Received
  FRI-378 Should we change the allocation policy for NASH patients? Assaf Issachar Received Received
  THU-378 Messenger RNA transcriptome profiling reveals a distinct phenotype of human bone marrow mesenchymal stem cell-derived hepatocytes Dongyan Shi Received Received
  THU-379 Deficiency of apoptosis-stimulating protein two of p53 promotes liver regeneration in mice by activating mammalian target of rapamycine Hongbo Shi Received Received
  SAT-379 Myeloid cells require gp130 signalling for protective anti-inflammatory functions during sepsis Tobias Otto Received Received
  THU-380 DLL4 restores damaged liver by protecting hepatocytes and enhancing cholangiocyte differentiation Jun Li Received Received
  SAT-380 Liver-resident memory CD8 T cells do not egress into hepatic venous blood Sergio Rodriguez Tajes Received Received
  FRI-380 Factors and models for predicting posthepatectomy liver failure in patients undergoing hepatic resection for hepatocellular carcinoma So-Hyun Kim Received Received
  THU-381 Characterization of regeneration in chronic hepatitis B before and after entecavir treatment in 20 patients Ian Wanless Received Received
  SAT-381 TAA-specific CD8 T-cell responses are inefficiently induced in hepatocellular carcinoma Catrin Tauber Received Received
  FRI-382 Biological assessment comprising alpha-fetoprotein, albumin-bilirubin score and C-reactive protein provides better prognostic competence than tumor size criteria in liver transplant patients with HCC Arno Kornberg Received Received
  THU-382 Use of facility-based provider initiated testing and counselling approach to ascertain viral hepatitis C status in high burden populations in Nigeria Chukwuemeka Agwuocha Received Received
  SAT-382 Crosstalk between liver NKT cells and liver sinusoidal endothelial cells Abdallah Yassin Received Received
  SAT-383 Human mesenchymal stem cells-derived exosomes attenuate liver ischemia/reperfusion injury by up regulation of notch-1-related autophagy in CD4 T cell Xiaomei Zhang Received Received
  THU-383 Dried blood spots: A useful tool for virologically caracterising the hepatitis C virus epidemic Elisa Martro Catala Received Received
  FRI-383 Role of traditional cardiovascular risk factors in predicting long term survival after liver transplantation Anoop Koshy Received Received
  FRI-384 Early cardiovascular mortality following liver transplantation: 30-year temporal trends from the Australian & New Zealand liver transplant registry Anoop Koshy Received Received
  THU-384 Clinical Performance of determine TM HBsAg 2 rapid test for hepatitis B detection Ana Avellon Received Received
  THU-385 Targeted screening for hepatitis C and predictors of advanced liver disease in the birth cohort in a tertiary primary care clinic Bersoux Sophie Received Received
  SAT-385 Production and characterization of humanl liver extracellular matrix hydrogels for in vitro culture of distinct human primary liver cell populations Niki Alevra Sarika Received Received
  FRI-385 Use of machine learning algorithms to predict HCC recurrence after liver transplantation: A proof of concept Phillipe Abreu Received Received
  FRI-386 Impact of acute-on-chronic liver failure on survival after liver transplantation Sebastián Marciano Received Received
  SAT-386 Insulin resistance in NK cells of F4 fibrosis inhibit mTOR expressions and are associated with decreased F-actin and killing ability in NASH patients Johnny Amer Received Received
  THU-386 Interim results of hepatitis prevention, control and elimination program in Ulaanbaatar, Mongolia Purevjargal Bat-Ulzii Received Received
  FRI-387 Risk factors associated with early post-operative acute kidney injury requiring renal replacement therapy following liver transplantation Jeremy Nayagam Received Received
  THU-387 Eliminating viral hepatitis C in Belgium: A mathematical model of the micro-elimination approach Dana Busschots Received Received
  FRI-388 Hepatitis C iInfected liver grafts transplanted into non-infected recipients are safe in the era of highly effective direct-acting antiviral therapy Heather ODell Received Received
  SAT-388 How to infuse heterologous human adult liver-derived progenitor cells safely? Louise Coppin Received Received
  THU-388 Annual healthcare costs double for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis patients who progress to advanced liver disease: A multivariable analysis of German real-world data Nandita Kachru Received Received
  THU-389 Assessment of hepatitis C screening strategies in different community settings in a Canadian metropolitan area Camelia Capraru Received Received
  SAT-389 Obeticholic acid reduces matrix metalloproteinases activity via iNOS modulation in hepatic ischemia/reperfusion injury Laura Giuseppina Di Pasqua Received Received
  FRI-389 Impact of coronary artery disease on long term mortality after liver transplantation Samarth Patel Received Received
  FRI-390 Management of dyslipidemia after liver transplantation Samarth Patel Received Received
  THU-390 Results of a birth cohort hepatitis C screening program in an academic emergency department in Canada Camelia Capraru Received Received
  SAT-390 Dengue virus protein NS3 activates hexokinase activity in hepatocytes to support virus replication Olivier Diaz Received Received
  FRI-391 Biliary calprotectin, lactoferrin and dimeric pyruvate kinase after liver transplantation are markers for biliary damage and predict graft survival Christian Rupp Received Received
  THU-391 Impact of early screening and treatment of hepatitis C virus and improvements in risk reduction on HCV transmission among HIV-infected men who have sex with men in France: A modeling approach Mathieu Castry Received Received
  SAT-391 The influence of Caveolin-1 on hepatocyte metabolism Mei Han Received Received
  THU-392 Building capacity within a hepatitis C treatment model. the validation process for a hepatitis C pre-treatment pharmacist assessment complex intervention toolkit Miriam Coghlan Received Received
  SAT-392 Dickkopf-1 from hepatocellular carcinoma cells promotes the angiogenic potential of endothelial cells by activating the VEGFR-2 signaling pathway Bora Jin Received Received
  FRI-392 Sarcopenia associated with worse pre-transplant psychosocial status and predicted post-transplant diabetes Yael Milgrom Received Received
  SAT-393 Melatonin attenuates dysregulation of the circadian clock pathway in liver fibrosis and progression to hepatocarcinoma Diana Isabel Sánchez Received Received
  FRI-393 Arterial stiffness in the assessment of cardiovascular risk after liver transplantation Lydia Sastre Received Received
  THU-393 HCV infection in Canadian immigrants: Characteristics and treatment outcomes of the CANUHC cohort David Mackie Received Received
  THU-394 Cancer risk among people with HIV, HBV, and/or HCV infections Maryam Darvishian Received Received
  FRI-394 Impact of early kidney dysfunction in the incidence of major cardiovascular events after liver transplantation Lydia Sastre Received Received
  SAT-395 Bone marrow-mesenchymal stem cells of cirrhosis patients show insulin resistance and bioenergetic exhaustion Deepanshu Maheshwari Received Received
  THU-395 Hepatitis C elimination by enhancing care and treatment among HIV co-infected individuals (the co-EC study): Real world evidence of decreasing HCV incidence and prevalence Joseph Doyle Received Received
  FRI-395 Etiology of liver disease affects weight gain after liver transplantation Mohammad Siddiqui Received Received
  FRI-396 Hypoadiponectinemia as a predictor of cardiovascular events in liver transplant recipients Mohammad Siddiqui Received Received
  THU-396 Hepatitis C screening among the population of Georgia within the national elimination program Sophia Surguladze Received Received
  SAT-396 Heat activation of hepatocytes is sufficient to account for post radiofrequency ablation induced tumorigenesis Aurelia Markezana Received Received
  THU-397 Screening strategies for hepatitis C virus elimination in Italy Ivane Gamkrelidze Received Received
  SAT-397 HIC-5 and GARP expression is upregulated by hydrogen peroxide and TGF beta in primary human hepatic stellate cells cultured on decellularized human liver 3D ECM scaffolds Simona Onali Received Received
  FRI-397 Sepsis is a major risk factor for delirium post liver transplantation Oliver Tavabie Received Received
  SAT-398 Pterostilbene reduces liver steatosis associated with obesity Saioa Gómez-Zorita Received Received
  FRI-398 Impact of sarcopenia and myosteatosis on post-transplant complications and survival Daniele Tavano Received Received
  THU-398 Circulating HCV resistant strains may result in long-term challenges to HCV elimination: A modeling study Ilias Gountas Received Received
  THU-399 First Belgian hepatitis E seroprevalence study shows low stable birth-cohort specific seroprevalence until 2014, with recent 2016-2018 increase in single centre estimates Erwin Ho Received Received
  FRI-399 Impact of a temporary cardiac arrest in a brain dead liver donor on liver transplantation results Elodie Timsit Received Received
  SAT-399 The profile on intracellular gangliosides correlates with the malignant phenotype of cholangiocarcinoma cells and modulates cells adhesion Chiara Raggi Received Received
  THU-400 Alanine-aminotransferase and 20-year risk of liver disease, cancer, ischemic heart disease, and diabetes in a Danish general population sample aged 30-49 years Morten Daniel Jensen Received Received
  SAT-400 IL-1 beta-mediated macrophage-hepatocyte crosstalk upregulates hepcidin under physiologic low oxygen levels Ins Silva Received Received
  FRI-400 Poor long term outcome of patients undergoing liver transplantation with preterminal renal dysfunction Marcel Touma Received Received
  THU-401 Changes in mortality due to chronic liver diseases in Spain during the period 2002-2016 Matthew Keys Received Received
  FRI-401 Direct-acting antiviral agents are not associated with an increased risk of hepatocellular carcinoma recurrence in liver transplant recipients with hepatitis C Chung Sang Tse Received Received
  SAT-401 Necroptosis signaling molecules regulate hepatic stellate cell activation via MLKL oligomerization-cell death independent pathway Sang Bong Ahn Received Received
  FRI-402 Outcomes after liver transplantation for argininosuccinate lyase deficiency: A longitudinal study Nipun Verma Received Received
  THU-402 Tailored message interventions using social marketing approach versus traditional message for increasing participation in viral hepatitis screening for Japanese workers Masaaki Korenaga Received Received
  THU-403 The consensus hepatitis C cascade of care: Methodology and initial findings from three countries Jeffrey V Lazarus Received Received
  FRI-403 Impact on post liver transplant outcomes of response to treatment with terlipressin and albumin in patients with hepatorenal syndrome Elia Vettore Received Received
  SAT-403 Polycyclic aromatic hydrocarbons can trigger a hepatocyte release of cytotoxic extracellular vesicles Nettie Van Meteren Received Received
  FRI-404 Multicenter experience evaluating outcomes of HCV-seropositive donors to HCV-seronegative recipients liver transplantation Karn Wijarnpreecha Received Received
  SAT-404 Discordant NS5a but not NS3 RASs profile in liver and plasma compartments of HIV/HCV genotype 1a/4d infected patients Giulia Morsica Received Received
  SAT-405 Genomic expression in circulating PBMCs of patients with hepatocellular carcinoma: Effect of ablative treatment Palmieri Vincenzo Received Received
  THU-405 Complications of chronic hepatitis B: Prevalence and disparities in a US health system cohort 2006-2016 Lora Rupp Received Received
  FRI-405 Predictors of outcomes for patients with non-alcoholic steatohepatitis undergoing liver transplantation in the United States Zobair Younossi Received Received
  SAT-406 Elevated biliary cholesterol in spite of hepatic ABCG5/G8 deficiency: Biliary lipid secretion in conditional knock-out mice Susanne N Weber Received Received
  THU-406 Cost-effectiveness analysis of treat all guidelines for chronic hepatitis C in Brazil Everton Macdo Silva Received Received
  THU-407 Implementation of a hepatitis C testing and linkage to care program in the Philadelphia jail system Lora Magaldi Received Received
  SAT-407 The Wilsons disease mouse (Atp7b-/-) has profound alterations in the hepatic metabolome and improved insulin sensitivity Ruth Wooton-Kee Received Received
  FRI-407 Elevating liver disease management in Egypt: A Project ECHO experience Noha Abdelgelil Received Received
  THU-408 Screening for viral immunity prior to immunosuppressive or biologic therapy Richard Manfready Received Received
  FRI-408 Self-stigma among patients with hepatitis B and C and its association with delayed diagnosis and treatment Shireen Abu Elhija Received Received
  FRI-409 Measuring the impact of a new liver specialist nursing service on patient care Dianne Backhouse Received Received
  SAT-409 Hepatic vein arrival time assessed by contrast-enhanced ultrasound in the non-invasive evaluation of portal hypertension Irene Andaluz García Received Received
  THU-409 Progress on scaling up testing and treatment for hepatitis C elimination in Punjab, Pakistan: Hepatitis prevention and treatment program Ammara Naveed Received Received
  SAT-410 Higher spleen iron content estimated by MRI T2 signal is associated with lower insulin-resistance in patients with dysmetabolic iron overload syndrome Edouard Bardou-Jacquet Received Received
  THU-410 Hepatitis B prevention of mother to child transmission integrated into antenatal care services in Mozambique Aude Nguyen Received Received
  FRI-410 Health literacy in outpatients with liver cirrhosis Palle Bager Received Received
  FRI-411 Nurse-led out-patient-clinic for patients with cirrhosis Hanne Bennick Received Received
  SAT-411 Clinical comparison and conversion of international normalized ratio and prothrombin index Paul Cales Received Received
  THU-411 Effectiveness of direct: Acting antivirals for the treatment of viral hepatitis C in Rwanda alida Ngwije Received Received
  SAT-412 The utility of the enhanced liver fibrosis test in alcoholic liver disease Declan Connoley Received Received
  THU-412 Iceland may already have reached the WHO 2030 targets for diagnosis and treatment of hepatitis C virus infection: Results from the treatment as prevention for hepatitis C (Trap HepC) program Sigurdur Olafsson Received Received
  FRI-412 A collaborative approach to increase access to hepatitis C treatment for the homeless population in Cornwall Helen Hampton Received Received
  SAT-413 Selected cytokines associated with chronic hepatitis b histological activity and fibrosis: A 78-week prospective study Xiao-Qin Dong Received Received
  THU-413 Service delivery for hepatitis C care: A systematic review and meta-analysis Ena Oru Received Received
  FRI-413 Integrating nurses in the management and care of patients with NAFLD: Better adherence and outcomes Anna Marie Hefner Received Received
  FRI-414 The impact of self and parental perception of body image on management in patients with NAFLD Anna Marie Hefner Received Received
  SAT-414 Baveno VI principle for noninvasive assessment of high risk varices is also applicable with shear wave elastography Oana Farcau Received Received
  THU-414 Low rate of treatment uptake amongst recently released prisoners with active HCV infection Timothy Papaluca Received Received
  THU-415 Changing patterns of liver disease in Wales: First results from the Wales liver disease registry Andrew Yeoman Received Received
  SAT-415 High levels of basement membrane remodelling (C4M) and low activity of wound healing (FPA) reflect fibrosis in alcoholic liver disease Natasja Gudmann Received Received
  FRI-415 People are scared: what they dont know dont hurt them. A qualitative exploration of reasons for low uptake of hepatitis C virus testing in an English prison Kathryn Jack Received Received
  THU-416 Use of telemedicine as a cost-effective program to achieve microelimination of hepatitis C virus infection among patients in a public healt care system in a low-income country JOSE LUIS PEREZ HERNANDEZ Received Received
  FRI-416 Assessment of written patient information pertaining to cirrhosis and its complications: A pilot study Lea Ladegaard Grnkjr Received Received
  SAT-416 Transient elastography in normal pregnancies: A prospective cohort study Hannes Hagstrm Received Received
  SAT-417 Serum levels of keratin 19 fragments (CYFRA 21-1) are elevated in advanced liver disease and predict poor survival Karim Hamesch Received Received
  FRI-417 Impact of a nurse educational program and accessibility in the management of patients with hepatocellular carcinoma under systemic treatment Neus Llarch Received Received
  FRI-418 Evaluating patients experience in liver transplantation: Role of the focus group technique Eva Lopez-Benages Received Received
  THU-418 Community-based screening for significant liver fibrosis among apparently asymptomatic adults in Delhi ARCHANA RAMALINGAM Received Received
  SAT-418 Splenic stiffness measurement using the ultrasound-fusion method Masashi Hirooka Received Received
  FRI-419 Is a lack of patient awareness holding back self-management of NAFLD? Bronwen Williams Received Received
  SAT-419 Endotrophin, a fragment of collagen type VI formation (PRO-C6) is associated with progression free survival and mortality in patients with hepatocellular carcinoma Signe Holm Nielsen Received Received
  THU-419 Prevalence of hepatitis B and C virus infections in Mongolian children and adolescents Khishigtogtokh Sereenendorj Received Received
  THU-420 Examination of patient and provider perceptions of hepatitis C care in Rwanda Janvier Serumondo Received Received
  SAT-420 The value of liver stiffness to platelet ratio and liver stiffness to spleen diameter to platelet ratio score compared with hepatic venous pressure gradient to predict the portal hypertension in patients with alcoholic and viral cirrhosis Soung Won Jeong Received Received
  FRI-420 A nurse-led advice and lifestyle intervention shows high levels of patient-reported satisfaction and motivation in community-based management of NAFLD Bronwen Williams Received Received
  THU-421 Lower alcohol taxes are associated with increased liver transplant listing Nicole Shen Received Received
  SAT-421 A novel score to patients for treatment in chronic hepatitis B: Results from a large Ethiopian cohort Asgeir Johannessen Received Received
  FRI-422 Genetic and pathophysiological factors leading to deficient acyl-CoA oxidase 2 (ACOX2) activity in hepatocytes, an alteration which causes oxidative and endoplasmic reticulum stress in liver cells Marta Alonso-Peña Received Received
  THU-422 Referral, treatment uptake and self-reported barriers in drug users diagnosed with active hepatitis C attending a low-threshold methadone program in Lisbon Mario Jorge Silva Received Received
  FRI-423 Role of antithrombin deficiency in splanchnic vein thrombosis Anna Baiges Received Received
  THU-423 Patient group monitoring of implementation of WHO viral hepatitis C recommendations: Identifying the gaps between policy and practice in Europe Adam Palayew Received Received
  SAT-423 Spleen extracellular volume fraction and platelet count/spleen volume ratio are accurate non-invasive markers of portal hypertension Christina Levick Received Received
  THU-424 HCV care cascade of PWIDs reached within the Global Fund needle and syringe program in Georgia Ketevan Stvilia Received Received
  FRI-424 Estrogen-containing oral contraceptives are associated with polycystic liver disease severity in pre-menopausal patients Lucas H.P. Bernts Received Received
  SAT-424 Spleen transient elastography and suprahepatic vein dumping index can be useful to identify patients without acute and chronic response to beta-blockers Elba Llop Received Received
  FRI-425 Maintenance therapy for Wilson disease with zinc: A comparison between zinc acetate and alternative zinc salts Michelle Camarata Received Received
  SAT-425 Serum metabolites as diagnostic biomarkers for cholangiocarcinoma, hepatocellular carcinoma and primary sclerosing cholangitis Rocio Macias Received Received
  SAT-426 Abnormal liver function tests: Current waiting times and comparison to iLFTs Iain Macpherson Received Received
  THU-426 Further validation of a liver traffic light test as a prediction model for survival and development of serious liver-related events Rochelle Sylvester Received Received
  FRI-426 Overexpression of c-Jun N-terminal Kinase-1 coincides with the acquisition of cholangiocytic markers in experimental cholangiocarcinoma Chaobo Chen Received Received
  THU-427 A community-based fast-track seek-test-treat program to enhance diagnosis and linkage to care for hepatitis C infection among people who inject drugs in Athens, Greece (ARISTOTLE HCV-HIV program) Vana Sypsa Received Received
  FRI-427 Liver humanized mouse as models for human metabolic liver diseases Raghuraman Chittoor Srinivasan Received Received
  SAT-427 The role of liver and spleen stiffness measurement in predicting hepatic decompensation after HCV eradication with direct antiviral agents therapy Federico Ravaioli Received Received
  THU-428 Routine point of care antenatal screening of hepatitis B virus in windhoek, Namibia: Feasibility of implementation Cynthia Tamandjou Received Received
  FRI-428 Prevalence and impact of sarcopenia in non-cirrhotic portal hypertension Simone Di Cola Received Received
  SAT-428 Prediction of liver stiffness by serum indexes in HCV-infected patients with or without HIV coinfection Nicolás Merchante Received Received
  SAT-429 Von Willebrand factor a noninvasive serum biomarker of portal pressure in cirrhosis: Evidence in human and rodent Xiaolong Qi Received Received
  FRI-429 Impact of allelic variants of platelet receptors and coagulation system genes in the development of clinical manifestations of Wilsons desease Saglara Fastovets Received Received
  THU-429 Serial testing with the enhanced liver fibrosis test and liver stiffness is cost-effective for detection of advanced alcoholic liver disease in primary care Maja Thiele Received Received
  THU-430 Changing prevalence of aetiological factors among Australians hospitalized for cirrhosis Patricia Valery Received Received
  FRI-430 Preclinical validation of copper 64 as a translational tool for evaluating the pharmacodynamics of VTX-801 genen therapy in Wilsons disease Gloria Gonzalez Received Received
  SAT-430 Spleen stiffness measured with ElastPQ point shear wave elastography has a good performance in predicting clinically significant portal hypertension in patients with primary sclerosing cholangitis Davide Roccarina Received Received
  SAT-431 Spleen stiffness measurement with ElastPQ point shear wave elastography has an excellent performance in predicting the presence of clinically significant portal hypertension in primary biliary cholangitis Francesca Saffioti Received Received
  FRI-431 Clinical spectrum of congenital hepatic fibrosis in children: 15 year experience from a tertiary care centre in north India Vybhav Gummadi Received Received
  THU-431 The burgeoning growth in cirrhosis-related hospitalization in Australia, 2008-2016 Patricia Valery Received Received
  THU-432 Viral sustained response in chronic hepatitis C did not reduce short term heatlh expediture Mercedes Vergara Gómez Received Received
  FRI-432 Current long-term outcome of 302 patients with noncirrhotic nontumoral extrahepatic portal vein thrombosis Guohong Han Received Received
  SAT-433 Portal venous velocity and platelet count as a simple non invasive tool to rule out the presence of varices needing treatment in patients with compensated cirrhosis Francesco Santopaolo Received Received
  FRI-433 Bevacizumab for the treatment of liver involvement in patients with hereditary hemorrhagic telangiectasia Assaf Issachar Received Received
  THU-433 Availability of information in drug labels for appropriate prescribing in patients with hepatic impairment Rianne Weersink Received Received
  THU-434 Poorly chosen upper limits of normal for alanine aminotransferase may burden the patient and health system unnecessarily Johannes Wiegand Received Received
  FRI-434 Role of next generation sequencing in the etiological diagnosis of splanchnic venous thrombosis Marta Magaz Received Received
  SAT-434 Liver stiffness measurement by transient elastography for the prognosis of hepatic carcinoma, decompensation, and death in patients with chronic liver diseases: A systematic review and meta analysis Yue Shen Received Received
  SAT-435 Quantitative MRCP imaging (MRCP): Accuracy, repeatability and reproducibility evaluation in healthy and liver disease patients gary woodward Received Received
  THU-435 A threshold analysis for the cost-effectiveness of hepatitis B and hepatitis C testing in emergency departments in the UK Jack Williams Received Received
  FRI-435 Progression to cirrhosis is not infrequent in patients with Wilsons disease despite treatment Zoe Mariño Received Received
  THU-436 The cost-effectiveness of one-time birth cohort screening for hepatitis C as part of the National Health Service health check programme for 40 to 74 year olds in England Jack Williams Received Received
  SAT-436 Inhibition of autophagy prolongs recipient survival through accelerating CD8 T-cell apoptosis in a rat liver transplantation model Xiaolong Chen Received Received
  FRI-436 Congenital porto-systemic shunts in children: Preliminary results from the IRCPSS Valérie Mclin Received Received
  THU-437 The Global Epidemiology on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in patients with type 2 diabetes mellitus: A systematic review and meta-analysis Zobair Younossi Received Received
  SAT-437 An mTor-based immunosuppression reduces the antiviral efficacy of NS3/4A and NS5A inhibitors for HCV genotype 1b treatment in vitro Alexandra Frey Received Received
  FRI-438 Histone deacetylase 5 methylation changes in mice and patients with Wilson disease Valentina Medici Received Received
  THU-438 The presence of type 2 diabetes is independently associated with impairment of patient-reported outcomes in patients with non-alcoholic steatohepatitis Zobair Younossi Received Received
  SAT-438 Effect of chondroitin sulfate in the rat liver cold ischemia and warm reperfusion injury Maria Pierre Received Received
  FRI-439 Factor V and VIII may predict the risk of recurrent splanchnic thrombosis in patients with non-cirrhotic chronic portal vein thrombosis of local and idiopathic etiology not receiving anticoagulation Bogdan Procopet Received Received
  THU-439 Variability in liver function test results and the risk of heart disease and mortality: A nationwide population-based study Su Jong Yu Received Received
  SAT-439 Identification of new drug targets to prevent ischemia-induced bile toxicity using a human biliary organoid model Floris Roos Received Received
  THU-440 Changing incidence of reported hepatitis B and its different trends amongest age groups in china from 2004-2016 Mingyuan Zhang Received Received
  FRI-440 Management of acute hepatic porphyria attacks in europe and united states: EXPLORE international, prospective, natural history study Eliane Sardh Received Received
  SAT-440 Molecular fingerprint of T cell-mediated and antibody-mediated rejection after human liver transplantation Richard Taubert Received Received
  THU-441 Site-specific structural N-glycan alterations limit CD73 nucleotidase activity in human hepatocellular carcinoma Karel Alcedo Received Received
  FRI-441 A novel heterozygous ABCB4, RUNDC3B and ABCB1 deletion associated with severe cholestatic liver disease in adults Benedetta Terziroli Beretta-Piccoli Received Received
  THU-442 Role of drug transporters in the chemoresistance of hepatoblastoma Maitane Asensio Received Received
  FRI-442 Acute hepatic porphyria disease manifestations and daily life impacts in EXPLORE international, prospective, natural history study Paolo Ventura Received Received
  FRI-443 Non-invasive fibrosis assessment in hyperferritinemia and hemochromatosis André Viveiros Received Received
  THU-443 Unexpected pro-tumorigenic effect of the chemokine Cxcl10 by modulation of tumor stroma in a murine model of HCC Elisa Brandt Received Received
  THU-444 Alteration of miRNAs expression in patients with HCV-related cirrhosis who developed HCC after therapy with DAAs Alessandra Brocca Received Received
  FRI-444 VTX-803 AAV-mediated correction of progressive familiar intrahepatic cholestasis type 3 in a clinically relevant mouse model Nicholas D Weber Received Received
  FRI-445 Safety and efficacy of trientine treatment in Wilson disease in patients withdrawn from d-Penicillamine: Final results from a prospective study Daphne van Scheppingen Received Received
  FRI-446 Reduction of hepatic Z-alpha1 antitrypsin by RNA interference prevents and reverses liver disease including hepatic mitochondrial injury in the PiZ mouse model Christine Wooddell Received Received
  THU-446 AMPK/PGC-1a-mediated metabolic reprogramming of hepatic stellate cells promote stemness of hepatocellular carcinoma via metabolite lactate shuttle Jianye Cai Received Received
  THU-447 DNA damage response CHK2 activates senescence cellular program and supports oxidative metabolism to drive hepatocellular carcinoma development Vinicio Carloni Received Received
  FRI-447 Clinical characteristics of liver cirrhosis and hepatocellular carcinoma occuring after Fontan operation Jun Sik Yoon Received Received
  FRI-448 Correction of a metabolic liver disease after ex vivo gene editing of defective human primary hepatocytes Mihaela Zabulica Received Received
  FRI-449 Complex ATP7B mutation patterns in Wilson disease and a evaluation of a yeast model for functional analysis of the individual variant Donghu Zhou Received Received
  THU-451 Characterization of cholangiocarcinoma primary, circulating and metastatic stem-like cells Margherita Correnti Received Received
  SAT-451 Gallbladder disease in the absence of cirrhosis is a significant risk factor for hepatocellular carcinoma Kenda Al-Assi Received Received
  FRI-451 Transarterial chemoembolization versus best supportive care for patients with hepatocellular carcinoma with portal vein tumour thrombus Xiao Xiang Received Received
  SAT-452 Analysis of intrahepatic sarcomatoid cholangiocarcinoma compared with intrahepatic adenocarcinoma Yanghyon Baek Received Received
  THU-452 TFOX, a novel TGF-beta target gene, switches TGF-beta activity toward EMT during tumor progression of human hepatocellular carcinoma Cedric Coulouarn Received Received
  FRI-452 Synergistic reduction of cancer proliferation and tumour growth in advanced murine hepatocellular carcinoma vis skewing and activation of innate and adoptive immunity Muhammad Khan Received Received
  FRI-453 Rapamycin promotes tumoricidal immunity in murine HCC by inducing M1-type macrophages and dentritic cells polarization and enhancement of cytotoxic T-cells Muhammad Khan Received Received
  SAT-453 Effects of sorafenib on pancreatic volume and their clinical implications in patients with hepatocellular carcinoma LUCA IELASI Received Received
  THU-453 Dissecting the landscape of (epi-)genetic alterations during sequential evolution of liver cancer Carolin Czauderna Received Received
  THU-454 Dual CCR2/CCR5 antagonism as macrophage targeted therapy in experimental hepatocellular carcinoma Helena Degroote Received Received
  SAT-454 Management of hepatocellular carcinoma in a real life multinational, longitudinal, observational study (TARGET-HCC) Stephanie Watkins Received Received
  THU-455 Metabolomic analysis by 1H-nuclear magnetic resonance spectroscopy suggest that there are 2 phenotypes of human hepatocellular carcinoma developed in non-alcoholic fatty liver disease according to fibrosis level (F0F1 vs F3F4) Aicha Demidem Received Received
  FRI-455 Effect of huaier granule on recurrence after curative resection of HCC: A multicenter, randomized clinical trial Qian Chen Received Received
  FRI-456 MELD score is the only predictor for 30-day mortality in patients with ruptured hepatocellular carcinoma treated by emergent transarterial embolization Ya-Ting Cheng Received Received
  SAT-457 Sarcopenia determines post-progression outcomes in advanced hepatocellular carcinoma after sorafenib failure Tsung-Yi Cheng Received Received
  THU-457 DoubleCortin/Like Kinase 1 (DCLK1) expression characterized specific cancer stem cell subpopulations of human cholangiocarcinoma primary cell cultures where its inhibition exerts anti-neoplastic effects Sabina Di Matteo Received Received
  FRI-457 Comparative long-term outcomes of laparoscopic liver resection and radio frequency ablation for hepatocellular carcinoma: Location of tumor matters Jai Young Cho Received Received
  SAT-458 Subtraction arterial images of hepatocyte-specific contrast-enhanced MRI: Added value for the diagnosis of hepatocellular carcinoma in the liver imaging reporting and data system v2018 Sang Hyun Choi Received Received
  FRI-458 Response evaluation using modified RECIST criteria predict outcomes better than RECIST 1.1 criteria in patients with HCC treated with Yttrium-90 radioembolization Hongjun Choi Received Received
  THU-458 Identification of relevant oncogenes in RAS-activated primary liver cancer using a targeted screening approach Ursula Ehmer Received Received
  FRI-459 Prognostic performance of ten non-invasive liver function tests in patients with hepatocellular carcinoma submitted to transarterial chemoembolization Pedro Costa-Moreira Received Received
  SAT-459 NASH as a risk factor for intrahepatic cholangiocarcinoma and its prognostic role: Case-control study Stefania De Lorenzo Received Received
  THU-459 Non-parenchymal TREM2 halts hepatocarcinogenesis through the inhibition of liver inflammation and hepatocyte proliferation Ibone Labiano Received Received
  SAT-460 Influence of sustained virological response in diagnostic performance of alpha-fetoprotein for hepatocellular carcinoma in patients with HCV-cirrhosis Ana Gómez Received Received
  THU-460 Longitudinal monitoring of cell-free DNA predicts for transarterial chemo-embolization failure in hepatocellular carcinoma Joanne Evans Received Received
  FRI-460 What are the predictive factors for long-term survivors with advanced hepatocellular carcinoma treated with sorafenib? Filipe de Sousa Damião Received Received
  THU-461 A diet-induced lean nonalcoholic steatohepatitis-associated hepatocellular carcinoma mouse model Elizabeth Vlock Received Received
  FRI-461 Thermal ablation is a safe and effective treatment for intrahepatic cholangiocarcinoma in patients with cirrhosis Álvaro Díaz-González Received Received
  SAT-461 HCC recurrence after DAA treatment in HCV patients Maria Guarino Received Received
  FRI-462 A multicenter international study of sorafenib treatment in patients with hepatocellular carcinoma and chronic kidney disease undergoing hemodialysis Álvaro Díaz-González Received Received
  THU-462 StARD1 is induced in human HCC and its overexpression aggravates cholesterol-mediated hepatocarcinogenesis in vivo José Fernandez-Checa Received Received
  SAT-462 Current non-invasive liver reserve models do not predict histological fibrosis severity in hepatocellular carcinoma Shu Yein Ho Received Received
  SAT-463 Albumin-bilirubin grade-based nomogram to predict tumor recurrence in patients with hepatocellular carcinoma Shu Yein Ho Received Received
  THU-463 Role of natural killer cells receptors on the development and progression of hepatocellular carcinoma Francesco Figorilli Received Received
  FRI-463 Long-term outcomes of irreversible electroporation for hepatocellular carcinoma Elliot Freeman Received Received
  FRI-464 Percutaneous microwave is better than radiofrequency ablation to obtain complete response in cirrhotic patients with very early and early hepatocellular carcinoma Silvia Gaia Received Received
  SAT-464 Predictive value of pretreatment neutrophil-to-lymphocyte ratio in survival of patients with hepatocellular carcinoma Young Mi Hong Received Received
  THU-464 NASH-related liver carcinogenesis is critically affected by hypoxia-inducible factor 2 alpha Beatrice Foglia Received Received
  FRI-465 The INCRNA H19 is an oncogenic driver of HCC in chronic inflammation-mediated mouse model Lika Gamaev Received Received
  SAT-465 The NIACE Score: A prognostic indicator in Hepatocellular carcinoma William Kemp Received Received
  THU-465 Variation of different histone deacetylases and the functional effects of HDAC inhibitors in hepatocellular carcinoma Kim Freese Received Received
  SAT-466 A meta-analysis of risk factors for intrahepatic and extrahepatic cholangiocarcinoma Shahid Khan Received Received
  FRI-466 A single centre experience of transarterial radioembolisation using Rhenium 188 for treatment of liver space occupying lesions Jeffey George Received Received
  THU-466 Epigenetic regulation of gene expression in a HCC-NASH murine model Antonio Gil-Gómez Received Received
  FRI-467 Optimal time-point of response assessment was associated with tumour burden in patients with unresectable hepatocellular carcinoma undergoing repeated transarterial chemoembolization Guohong Han Received Received
  SAT-467 Pathologic identity of indeterminate hepatic nodules on dynamic computed tomography images of cirrhotic patients undergoing liver transplantation: A potential bias in evaluating suitability for transplantation Ha Il Kim Received Received
  THU-467 Comparison of the immune tumour microenvironment between primary and metastatic hepatocellular carcinoma: Implication for biomarker research ofimmunotherapy Chia-Wei Chen Received Received
  FRI-468 Identifying optimal candidates for combining transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma: A multicenter observational study Guohong Han Received Received
  THU-468 SLU7 controls genome integrity: New role of truncated SRSF3 proteins Maddalen Jimenez Received Received
  SAT-468 Prognostic value of post-treatment liver stiffness in hepatocellular carinoma with histologically confirmed cirrhosis Jung Il Lee Received Received
  THU-469 Nanoparticular bisphosphonate to ively target and repolarize liver macrophages for efficient anti-tumour response Leonard Kaps Received Received
  SAT-469 Frequency of TP53, CTNNB1, and TERT promoter mutations in patients with hepatocellular carcinoma from Southern Italy Daniele Lombardo Received Received
  FRI-469 Vitamin K dosing could improve anti-cancer outcome of transarterial chemoembolization for patients with hepatocellular carcinoma-an open label, randomized, phase II study Yoshimichi Haruna Received Received
  SAT-470 Circulating levels of soluble urokinase plasminogen activator receptor (suPAR) predict outcome after resection of cholangiocarcinoma Sven Loosen Received Received
  FRI-470 External beam radiotherapy as an effective and safe treatment in all stages of hepatocellular carcinoma with cirrhotic liver disease : A single institution experience Clémence Hollande Received Received
  THU-470 The mRNA-binding protein tristetraprolin promotes hepatocarcinogenesis but inhibits tumour progression in liver cancer Sonja Kessler Received Received
  FRI-471 Regorafenib may enhance efficacy of anti-program cell death-1 therapy in hepatocellular carcinoma through modulation of macrophage polarization Chia-Wei Chen Received Received
  SAT-471 Hepatic adenomatosis increases risk of hepatic adenoma bleeding Chelsea McDermott Received Received
  THU-471 Establishment of a short-termed orthotopic transplantation model in C57/B6 mice that recapitulates characteristic features of human intrahepatic cholangiocarcinoma Theresa Wirtz Received Received
  FRI-472 ALBI grade determines survival of nivolumab-treated patients with advanced hepatocellular carcinoma: a real-world observational study Yi-Hsiang Huang Received Received
  THU-472 Pharmacological inhibition of PIM1 suppresses tumor progression and enhances chemosensitivity in heptaocellular carcinoma Ming Sum Leung Received Received
  SAT-472 Massive sequencing of circulating DNA as a potential tool for diagnosis and follow-up in patients with hepatocellular carcinoma Beatriz Minguez Received Received
  FRI-473 Safety and effectiveness of regorafenib in recurrent HCC after liver transplantation and progression on sorafenib: A real-life multicentre study Massimo Iavarone Received Received
  SAT-473 Transition to the era of direct-acting antiviral changes in the prognosis of patients with hepatitis C virus-related hepatocellular carcinoma Yoshifumi Miura Received Received
  THU-473 Role of intracellular lysyl oxidase in progression of primary liver cancer Monika Lewinska Received Received
  FRI-474 AGT gene polymorphisms predict early dose modification of sorafenib for dermatological adverse events: towards tailored medicine for patients with hepatocellular carcinoma Massimo iavarone Received Received
  SAT-474 Misdiagnosis of focal liver lesions by means of CEUS Tudor-Voicu Moga Received Received
  THU-474 Existence of intratumoral teriary lymphoid structures predicts better prognosis in Barcelona clinic of liver cancer stage 0-a hepatocellular carcinoma Hui Li Received Received
  SAT-475 Clinical validation of the role of contrast-enhanced ultrasound in the EASL guidelines for the diagnosis of hepatocellular carcinoma Lorenzo Mulazzani Received Received
  FRI-475 Experience impacts on reasons leading to sorafenib discontinuation and chance of long-term response Ielasi Luca Received Received
  FRI-476 Repeated surgical resection versus radiofrequency ablation for recurrent hepatocellular carcinoma after surgical resection : A propensity score matching analysis Chang Ke-Bin Received Received
  THU-476 Modeling cancer stem cell and differentiated cancer cell phenotypes in liver cancer organoids Ruby Lieshout Received Received
  SAT-477 Impact of skeletal muscle quality and quantity on outcomes following curative therapy of hepatocellular carcinoma Tomoaki Nakajima Received Received
  THU-477 Sumoylation/acetylation drives forward oncogenic role of LKB1 in Liver Fernando Lopitz Otsoa Received Received
  FRI-477 Factors associated with good post progression survival in post-sorafenib progressed advanced hepatocellular carcinoma patients not eligible for regorafenib Chang Wook Kim Received Received
  SAT-478 Comparison of prediction models for hepatocellular carcinoma development in treatment naive chronic hepatitis B patients with cirrhosis Hyunwoo Oh Received Received
  THU-478 CXCL5 induced by transforming growth factor-beta and Axl signalling causes neutrophil extracellular trap formation in hepatocellular carcinoma Wolfgang Mikulits Received Received
  FRI-478 Survival outcomes of TACE in treatment-naive and recurrent HCC after curative resection: A propensity score-matched analysis David Sooik Kim Received Received
  THU-479 The hepatocyte specific role of the NRF2/KEAP1 axis for HCC Progression during chronic liver disease Antje Mohs Received Received
  FRI-479 Hepatocellular carcinoma with extrahepatic metastasis: Are there still candidates for transarterial chemoembolization as an initial treatment? Jihye Kim Received Received
  SAT-479 Analysis of the relationship between serum creatinine/cystatin C ratio and muscle mass in patients with hepatocellular carcinoma Hirotaka Oura Received Received
  SAT-480 Long-term survivors in patients with hepatocellular carcinoma: An ITA.LI.CA report Filippo Pelizzaro Received Received
  THU-480 Imaging mechanical stiffness and molecular landscapes of cancer stem cell niches in human hepatocellular carcinomas Orlando Musso Received Received
  SAT-481 Intratumoral mast cell infiltration and recurrence of hepatocellular carcinoma in patients undergoing orthotopic liver transplantation Nataliya Rohr-Udilova Received Received
  THU-481 Classification of intrahepatic cholangiocarcinoma microenvironment based on immune cell and tumor stromal features